CA2084411A1 - Peptide library and screening systems - Google Patents

Peptide library and screening systems

Info

Publication number
CA2084411A1
CA2084411A1 CA002084411A CA2084411A CA2084411A1 CA 2084411 A1 CA2084411 A1 CA 2084411A1 CA 002084411 A CA002084411 A CA 002084411A CA 2084411 A CA2084411 A CA 2084411A CA 2084411 A1 CA2084411 A1 CA 2084411A1
Authority
CA
Canada
Prior art keywords
peptide
bacteriophage
peptides
receptor
phage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002084411A
Other languages
French (fr)
Inventor
William J. Dower
Steven E. Cwirla
Ronald W. Barrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymax Technologies NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2084411A1 publication Critical patent/CA2084411A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/675Beta-endorphins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/02Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Abstract

Peptide which bind to selected receptors are identified by screening libraries which encode a random or controlled collection of amino acids. Peptides encoded by the libraries are expressed as fusion proteins of bacteriophage coat proteins, and bacteriophage are then screened against the receptors of interest. Peptides having a wide variety of uses, such as therapeutic or diagnostic reagents, may thus be identified without any prior information on the structure of the expected ligand or receptor.

Description

2 ~ 8 ~ PCI/US91/W384 PEPTIDE LIBRARY AND SCREENING SYSTEMS

Field of the Invention The present invention relates generally to methods for selecting peptide ligands to receptor molecules of interest and, more particulaxly, to methods for generating and screening large peptide libraries for peptides with desired binding characteristics.

Backaround of the Invention As molecular biology has helped to define regions of proteins that contribute to a particular biological activity, it has become desirable to synthesize short peptides to mimic ~or inhibit) those ~ activities. Many of the disadvantages encountered in r therapeutic, diagnostic and industrial settings with purified proteins, or those produced by recombinant -means, could easily be avoided by short synthetic peptides. For instance, synthetic peptides offer advantages of specificity, convenience of sample or bulk preparation, lower relative cost, high degree of purity, and long shelf-life.
Despite the great promise of synthetic peptides, the technology remains, to a large extent, a laboratory tool. Precise sequence and binding data are not available for most proteins of significant medical, agricultural or industrial interest. Even when the sequence of a protein is known, the process of ., . ~ .

, - -~. ~, . , .: :
''" `; " ' ' '. ', .,'~` ~ ' ;
- , . : .

2~d,~
WO9l/19818 PCT/US91/~ _ identifying short sequences which are responsible for or contribute to a biological activity may be extremely tedious, if not nearly impossible in many instances.
Thus, the ability to generate and efficiently screen very large collections of peptides for desired 5 binding activities would be of enormous interest. It would enable the identification of novel agonists and antagonists for receptors, the isolation of specific inhibitors of enzymes, provide probes for structural and functional analyses of binding sites of many proteins, and ligands for man~ other compounds employed in a wide variety of applications.
The generation of large numbers of peptide sequences by the cloning and expression of randomly-generated mixtures of oligonucleotides is possible in the appropriate recombinant vectors. See, e.g., Oliphant et al., Gene 44:177-183 (1986). Such a large number of compounds can be produced, however, that methods for efficient physical and genetic selection are required.
Without such methods the usefulness of these large peptide libraries in providing ligands of potential interest may be lost. The present invention provides methods for efficient screening and selection from a large peptide library, fulfilling these and other related needs.

Summary of the Invention The present invention provides novel methods and compositions for identifying peptides which bind to preselected receptor molecules. The peptides find a variety of therapeutic, diagnostic and related uses, e.g., to bind the receptor or an analogue thereof and inhibit or promote its activity.
In one embodiment the invention relates to methods for identifying the peptides which bind to a . .: . . , : . . ., ................... . - . : .

' ': . ' , . ` ' ': . ' . :. .,. ': ~ : -, , .

WO91/19818 2 ~ ~ ~ a ~ ~ PCT/US91/~
.

preselected receptor. In certain aspects the methods generally comprise constructing a bacteriophage expression vector which comprises an oligonucleotide library of at least about 106 members which encode the S peptides. The library member is joined in reading frame to the 5' region of a nucleotide sequence encoding an outer structural protein of the bacteriophage.
Appropriate host cells are transformed with the expression vectors, generally by electroporation, and the transformed cells cultivated under conditions suitable for expression and assembly of bacteriophage. Using an affinity screening process, bacteriophage library members are contacted with the preselected receptor under conditions conducive to specific peptide-receptor binding, and bacteriophage whose coat proteins have peptides which bind the receptor molecule are selected.
The nucleotide sequence which encodes the peptide on the selected phage may then be determined. By repeating the affinity selection process one or more times, the peptides of interest may be enriched. By increasing the stringency of the selection, e.g., by reducing the valency of the peptide-phage interaction towards substantial monovalency, peptides of increasingly higher affinity can be identified.
In another aspect the methods are concerned with expression vectors having the oligonucleotide library members joined in reading ~rame with a nucleotide sequence to encode a fusion protein, wherein ~he library member represents the 5' member of the fusion and the 3' member comprises at least a portion of an outer structural protein of the bacteriophage. The first residue of the peptide encoded by the library member may be at the 5'-ter~inus of the sequence encoding the phage coat protein. In preferred embodiments, where phage proteins are initially expressed as preproteins and then processed by the host cell to a mature protein, the library members are inserted so as to lea~e the peptide . : . . . .

. ~: ~ ' ` ~ , . .

2 0 ~
W09~/19818 PCT/US91/04 ; encoded thereby at the N-terminus of the mature phage protein after processing or a protein substantially homologous thereto.
The invention also concerns host cells transformed with a bacteriophage expression vector having an oligonucleotide library member, joined in reading ~rame to the 5' region of a nucleotide se~uence encoding an outer structural protein of the bacteriophage, wherein the library member encodes a peptide of at least about five to twenty-five amino acids.
Generally, the oligonucleotide library of the invention comprises a variable codon region which encodes for the peptides of interest, and may optionally comprise sequences coding for one or more spacer amino acid residues, such as Gly. The variable region may be encoded by (NNK)~ or (NNS)~, where N is A, C, G or T, K is G or T, S is G or C, and x is from 5 to at least about 8.
In certain preferred embodiments the variable region of s the oligonucleotide library member encodes a hexa-peptide. The variable codon region may also be prepared from a condensation of activated trinucleotides.

~ '.
25 Brief Description of the Drawinas ~: .
Fig. l depicts the construction of an oligonucleotide library. (A) The vector fAFFl contains two non-complementary BstX~ sites separated by a 30 bp stuffer fragment. Removal of the BstXI fragment allows crien~ed ligation of oligonucleotides with the appropriate cohesive ends. SB) The oligonucleotide ON-49 was annealed to two "half-site" fragments to form cohesive termini complementary to BstXI sites l and 2 in 3S the vector. The gapped structure, where the single-stranded region comprises the variable hexacodon sequence . -.. . :. . . .... . .. . . . .,...... .. . ...... . ...... . ... . . : ..
-: :: . . - - . . . . .. .. . .

WO91/19818 2 ~ PCT/US91/04 and a 2 (gly) codon spacer, was ligated to the vector and electro-transformed into E. coli.
Fig. 2 depicts the amino acid sequences (deduced from DNA sequence) of the N-terminal hexapeptides on pIII of infectious phage randomly selected from the library. Sequences begin at the signal peptidase site. Single letter code for amino acids is A
(Ala), C (Cys), D (Asp), E (Glu), F (Phe), G (Gly), H
(His), I (Ile), K (Lys), L (Leu), M (Met), N (Asn), P
(Pro), Q (Gln), R (Arg), S (Ser), T (Thr), V (Val), W
(Trp), Y (Tyr).
Fig. 3 illustrates the composite DNA ~equence of the variable region of pools of (A) infectious phage from the library, and (B) phage recovered from l, 2, or 3 rounds of panning on mAB 3E7. Phage were amplified as tetracycline resistant colonies and DNA from a pool of phage derived from several thousand of these colonies was isolated and sequenced. The area of the sequencing gel corresponding to the cloning site in geneIII is displayed. A sequencing primer was annealed to the phage J DNA -40 bases to the 3' side of the cloning site. The - actual readout of the gel is the sequence complementary to the coding strand. For clarity of codon identification, the lanes may be read as C, T, A, G, left to right and 5' to 3', top to bottom, to identify the sequence of the coding (+) strand.
Fig. 4 shows the amino acid seguences (deduced from DNA sequence) of the N-terminal peptides of pIII of 51 phage isolated by three rounds of panning on mAB 3E7.
Fig. 5 illustrates the results of phage sandwich ELISAs for YGGFL- and YAGFAQ-phage with - biotinylated monoclonal antibody 3E7 IgG (Fig. 5A) or 3E7 Fab fragments ~Fig. 5B) immobilized at maximal density on streptavidin coated wells and labeled polyclonal anti-phage antibodies to detect bound phage.
`~ Fig. 6 illustrates the results of phage sandwich ELISAs which compare the effect of 3E7 Fab `

.: - . . ~ ., : . . . .. .

WO91/19818 ~ a ~ i PCT/US91/04~ _ concentration at 5 nM (Fig. 6A) and 50 pM (Fig. 6B) and wash times (minutes) on recoveries of YGGFL- and YAGFA~-phage.
Fig. 7 shows 3E7 Fab dissociation from phage bearing peptides of known affinity, YGGFI, and YGFWGM.

Description of the Preferred Embodiments Methods and compositions are provided for identifying peptides which bind to receptor molecules of interest. The peptides are produced from oligonucleotide libraries which encode peptides attached to a bacteriophage structural protein. A method of affinity enrichment allows a very large library of peptides to be screened and the phage carrying the desired ~eptide(s) selected. The nucleic acid may then be isolated from the phage and the variable region of the oligonucleotide library member sequenced, such that the amino acid - 20 sequence of the desired peptide is deduced therefrom.
Using these methods a peptide identified as having a binding affinity for the desired molecule may then be synthesized in bulk by conventional means.
By identifying the peptide de novo one need not know the sequence or structure of the receptor molecule or the sequence of its natural binding partner. Indeed, for many "receptor" molecules a binding partner has not yet been identified. A significant advantage of the present invention is that no prior information regarding an expected ligand structure is required to isolate peptide ligands of interest. The peptide identified will thus have biological activity, ~hich is meant to include at least specific binding affinity for a selected receptor molecule, and in some instances will further include the ability to block the binding of other compounds, to stimulate or inhibit metabolic pathways, to ' W091/19818 PCT/US91/W~
2 ~

act as a signal or messenger,-to stimulate or inhibit cellular activity, and the like.
The number of possible receptor molecules for which peptide ligands may be identified by means of the present invention is virtually unlimited. For example, the receptor molecule may be an antibody ~or a binding portion thereof). The antigen to which the antibody binds may be known and perhaps even sequenced, in which case the invention may be used to map epitopes of the antigen. If the antigen is unknown, such as with certain autoimmune diseases, for example, sera or other fluids from patients with the disease can be used in the present methods to identify peptides, and consequently the antigen which elicits the autoimmune response. It is also possible using these methods to tailor a peptide to fit a particular individual's disease. Once a peptide has been identified it may itself serve as, or provide ~- the basis for, the development of a vaccine, a therapeutic agent, a diagnostic reagent, etc.
The present invention can identify peptide ; ligands for a wide variety of substances in addition to - antibodies. ~hese include, by way of example and not limitation, growth factors, hormones, enzymes, interferons, interleukins, intracellular and intercellular messengers, lectins, cellular adhesion molecules and the like, as well as the ligands for the corresponding receptors of the aforementioned molecules.
It will be recognized that peptide ligands may also be ` identified by the present invention for molecules which are not peptides or proteins, e.g., carbohydrates, non-protein organic compounds, metals, etc. Thus, although antibodies are widely available and conveniently manipulated, they are merely representative of receptor mole~ules for which peptide ligands can be identified by means of the present invention.
; An oligonucleotide library, prepared according to the criteria as described herein, is in~erted in an ... .. . . . . . . .
.. . . . . .. . , ~ . ~ :

2'~ i d ~ ~
WO91/19818 PCTtUS91/04~ _ appropriate vector encoding a bacteriophage structural protein, preferably an accessible phage protein/ such as a bacteriophage coat protein. Although one skilled in the art will appreciate that a variety of bacteriophage may be employed in the present invention, in preferred embodiments the vector is, or is derived ~rom, a filamentous bacteriophage, such as, for example, ~1, fd, Pfl, M13, etc. In a more preferred embodiment the filamentous phage is fd, and contains a selectable marker such as tetracycline (e.g., "fd-tet"). The fd-tet vector has been extensively described in the literature. See, for example, Zacher et al., Gene 9:127-140 (1980), Smith et al., Science 228:1315-1317 (1985) and Parmley and Smith, Gene 73:305-318 (1988), each incorporated by reference herein.
The phage vector is chosen to ~ontain or is constructed to contain a cloning site located in the 5' region of the gene encoding the bacteriophage structural protein, so that the peptide is accessible to receptors in an affinity selection and enrichment procedure as described below. As the structural phage protein is preferably a coat protein, in phage fd the preferred coat protein is pIII. Each filamentous fd phage is known to ! have up to four or five copies of the pIII protein.
An appropriate vector allows oriented cloning of the oligonucleotide sequences which encode the peptide so that the peptide is expressed at or within a distance of about 100 amino acid residues of the N-terminus of the mature coat protein. The coat protein is typically expressed as a preprotein, having a leader sequence.
Thus, desirably the oligonucleotide library is inserted so that the N-terminus of the processed bacteriophage outer protein is the first residue of the peptide, i.e., between the 3'-terminus of the sequence encoding the leader protein and the 5'-terminus of the sequence encoding the mature protein or a portion of the 5' terminus.

' .: .
.
. .

.

WO9ltl9818 2 U ~ ~ 4 ~ ~ PCT/US91/04~

The library is constructed by cloning an oligonucleotide which contains the variable region of library members (and any spacers, framework determinants, etc. as discussed below) into the selected cloning site.
S Using known recombinant DNA techniques (see generally, Sambrooke et al., Molecular Clonina A Laboratory Manual, 2d ed., Cold Sprin~ Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, incorporated by reference herein), an oligonucleotide may be constructed which, inter alia, removes unwanted restriction sites and adds desired ones, reconstructs the correct portions of any sequences which have been removed (such as a correct signal peptidase site, for example), inserts the spacer conserved or framework residues, if any, and corrects the translation frame (if necessary) to produce active, infective phage.
The central portion of the oligonucleotide will generally contain one or more of the variable region domain(s) and the spacer or framework residues. The sequences are ultimately expressed as peptides (with or without spacer or framework residues) fused to or in the N-terminus of the ~ature coat protein on the outer, accessible surface of the assembled bacteriophage particles.
The variable region domain of the oligonucleotide comprises the source of the library. The size of the library will vary according to the number of variable codons, and hence the size of the peptides, which are desired. Generally the library will be at least about 106 members, usually at least 107, and typically 108 or more members. To generate the collection of oligonucleotides which forms a series of codons encoding a rando~ collection of amino acids and which is ultimately cloned into the vector, a codon motif is used, such as (NNR)~, where N may be A, C, G, or T (nominally ` equimolar), K is G or T (nominally equimolar), and x is typically up to about 5, 6, 7, or 8 or more, thereby producing libraries of penta-, hexa-, hepta-, and octa-peptides or more. The third position may also be G or C, . . ' : . . ' .

2 ~3 ~
WO91/19818 PCT/US91/04~ _ designated "S". Thus, NNK or NNS (i) code for all the amino acids, (ii) code for only one stop codon, and (iii) reduce the range of codon bias from 6:l to 3:l. It should be understood that with longer peptides the size of the library which is generated may bec~me a constraint in the cloning process and thus the larger libraries can be sampled, as described hereinbelow. The expression of peptides from randomly generated mixtures of oligonucleotides in appropriate recombinant vectors is discussed in Oliphant et al., Gene 44:177 183 (1986), incorporated herein by reference.
An exemplified codon motif (NNK)~ produces 32 codons, one for each of 12 amino acids, two for each of five amino acids, three for each of three amino acids and one (am~er) stop codon. Although this motif produces a codon distribution as equitable as available with standard methods of oligonucleotide synthesis, i_ results in a bias against peptides containing one-codon residues.
For example, a complete collection of hexacodons contains one sequence encoding each peptide made up of only one-codon amino acids, but contains 729 (36) sequences encoding each peptide with only three-codon amino acids.
An alternative approach to minimize the bias against one-codon residues involves the synthesis of 20 activated tri-nucleotides, each representing the codon for one of the 20 genetically encoded amino acids. These are synthesized by convantional means, removed from the support but maintaining the base and 5-H0-protecting groups, and activating by the addition of 3'0-phosphoramidite (and phosphate protection with b-` cyanoethyl groups) by the method used for the activation ; of mononucleosides, as generally described in McBride and Caruthers, Tetrahedron Letters 22:245 tl983), which is incorporated by reference herein. Degenerate "oligocodons" are prepared using these trimers as building blocks. The trimers are mixed at the desired molar ratios and installed in the synthesizer. The ,: ~ .. . ' . : ' ... .. ..

WO 91tl9818 2 ~ i PCT/US911 ratios will usually be approximately equimolar, but may be a controlled unequal ratio to obtain the over- to under-representation of certain amino acids coded for by the degenerate oligonucleotide collection. The S condensation of the trimers to form the oligocodons is done essentially as described for conventional synthesis employing activated mononucleosides as building blocks.
See qenerallY, Atkinson and S~ith, Oliqonucleotide Svnthesis, M.J. Gait, ed. p35-82 (lg84). Thus, this procedure generates a population of oligGnucleotides for cloning that is capable of encoding an equal distribution (or a controlled unequal distribution) of the possible peptide sequences. ~his approach may be especially useful in generating longer peptide sequences, since the range of bias produced by the (NNK) 6 motif increases by three-fold with each additional amino acid residue.
When the codon motif is (NNK)~, as defined above, and when x equals 8, there are 2.6 x lOl possible octa-peptides. A library containing most of the octa-peptides may be difficult to produce. Thus, a sampling of the octa-peptides ~ay be accomplished by constructing a subset library using of about .1%, and up to as much as 1%, 5% or 10% of the possible sequences, which subset of recombinant bacteriophage particles is then screened. As the library size increases, smaller percentages are acceptable. If desired, to extend the diversity of a subset library the recovered phage subset may be subjected to mutagenesis and then subjected to subsequent ~` rounds of screening. This mutagenesis step may be accomplished in two general ways: the variable region of the recovered phage may be mutagenized, or additional variable amino acids ~ay be added to the regions ` adjoining the initial variable sequences.
A variety of techniques can be used in the present invention to diversify a peptide library or to diversify around peptides found in early rounds of panning to have sufficient binding activity. In one :.
~, .

. . , . ~ . , . . ~ - . , - . --:- . :,.. ., , . ,,, . ,: . . .
-, ;........ , : : : .
~ . , . . , .: , , ~ , . , : .
.. . . . .. .

2 a ~
WO9l/19818 PCT/US91/~

approach, the positive phage (those identified in an early round of panning) are sequenced to determine the identity of the active peptides. Oligonucleotides are then synthesized based on these peptide sequences, employing a low level of all bases incorporated at each step to produce slight variations of the primary oligonucleotide sequences. This mixture of (slightly) degenerate oligonucleotides is then cloned into the affinity phage as described herein. This method produces systematic, controlled variations of the starting peptide sequences. It requires, however, that individual positive phage be sequenced before mutagenesis, and thus is useful for expanding the diversity of small numbers of recovered phage.
Another technique for diversifying around the recognition kernal of the selected phage-peptide involves the subtle misincorporation of nucleotide changes in the peptide through the use of the polymerase chain reaction (PCR) under low fidelity conditions. A protocol of Leung at al., Technique 1~ 15 (1989) alters the ratios of nucleotides and the addition of manganese ions to produce a 2% mutation frequency. Yet another approach for diversifying the selected phage involves the mutagenesis of a pool, or subset, of recovered phage. Phage ; 25 recovered from panning are pooled and single stranded DNA
is isolated. The DNA is mutagenized by treatment with, e.g., nitrous acid, formic acid, or hydrazine. These treatments produce a variety of damage in the DNA. The damaged DNA is then copied with reverse transcriptase which misincorporates bases when it encounters a site of damage. The segment containing the sequence encoding the varia~le peptide is then isolated by cutting with `~ restriction nuclease~s) specific for sites flanking the variable region. This mutagenized segment is then recloned into undamaged vector DNA in a manner similar to that described herein. The DNA is transfo~med into cells and a secondary library is constructed as described. The ,~ . , , . :

WO91/19~18 2 0 ~ PCT/US91/04 general mutagenesis method is described in detail in Myers, et al., Nucl. Acids Res. 13:3131-3145 (1985), Myers et al., Science 229:242-246 (1985), and Myers, Current Protocols in Molecular Biology Vol I, 8.3.1 -8.3.6, F. Ausebel, et al., eds, J. Wiley and Sons, New York (1989), each of which are incorporated herein by reference.
In the second general approach, that of adding additional amino acids to a peptide or peptides found to be active, a variety of methods are available. In one, the sequences of peptides selected in early panning are deter~,ined individually and new oligonucleotides, incorporating the determined sequence and an adjoining degenerate sequence, are synthesized. These are then cloned to produce a secondary library.
In another approach which adds a second variable region to a pool of peptide-bearing phage, a restriction site is installed next to the primary variable region. Preferably, the enzyme should cut outside of its recognition sequence, such as BspMI which cuts leaving a four base 5' overhang, four bases to the 3' side of the recognition site. Thus, the recognition site may be placed four bases from the primary degenerate region. To insert a second variable region, the pool of phage DNA is digested and blunt-ended by filling in the overhang with Klenow fragment. Double-stranded, blunt-ended, degenerately synthesized oligonucleotide is then ligated into this site to produce a second variable region juxtaposed to the primary variable region. This secondary library is then amplified and screened as before.
While in some instances it may be appropriate to synthesize peptides having contiguous variable regions ~` to bind certain receptors, in other cases it may be ~ 35 desirable to provide peptides having two or more regions i of diversity separated by spacer residues. For example, the variable regions may be separated by spacers which - : ... , . : .
.. . .... .. . .. , : . :
:, ~ . ,~ : . .. . ... . . .
.: - ' : , ,, ,~ . ~
.. .. : . ..

W09t/19818 2~a~ L PCT/US91/04~ _ allow the diversity domains of the peptides to be presented to the receptor in different ways. The distance between variable regions may be as little as one residue, sometimes five to ten and up to about lO0 residues. For probing a large binding site the variable regions may be separated by a spacer of residues of 20 to 30 amino acids. The number of spacer residues when present will preferably be at least two, typically at least three or more, and often will be less than ten, more often less than eight residues.
Thus, an oligonucleotide library having variable domains separated by spacers can be represented by the formula:
(NNR)y-(abc)n~ K)z, where N and K are as defined previously (note that s as defined previously may be substituted for K), and y + z is equal to about 5, 6, 7, 8, or more, a, b and c represent the same or different nucleotides comprising a codon encoding spacer amino acids, n is up to about 20 to 30 amino acids or more.
The spacer residues may be somewhat flexible, comprising oligo-glycine, for example, to provide the diversity domains of the library with th~ ability to interact with sites in a large binding site relatively unconstrained by attachment to the phage protein. Rigid spacers, such as, e.g., oligo-proline, may also be inserted separately or in combination with other spacers, including Gly. It may be desired to have the variable domains close to one another and use a spacer to orient the variable domain with respect to each other, such as by employing a turn between the two sequences, as might be provided by a spacer of the seguence Gly-Pro-Gly, for example. To add stability to such a turn, it may be desirable or necessary to add Cys residues at either or both ends of eaGh variable region. The Cys residues would then form disulfide bridges to hold the variable ; regions together in a loop, and in this fashion may also ' .
. .

WO91/19818 2 ~ PCT/USg~/04~W

serve to mimic a cyclic peptide. Of course, those skilled in the art will appreciate that various other types of covalent linkages for cyclization may also be accomplished.
The spacer residues described above can also be situated on either or both ends of the variable nucleotide region. For instance, a cyclic peptide may be accomplished without an intervening spacer, by having a Cys residue on both ends of the peptide. As above, flexible spacers, e.g., oligo-glycine, may facilitate interaction of the peptide with the selected receptors.
Alternatively, rigid spacers may allow the peptide to be presented as if on the end of a rigid arm, where the number of residues, e.g., Pro, determines not only the length of the arm but also the direction for the arm in which the peptide is oriented. Hydrophilic spacers, made up of charged and/or uncharged hydrophilic amino acids, (e.g., Thr, His, As~, Gln, Arg, Glu, Asp, Met, ~ys, etc.), or hydrophobic spacers of hydrophobic amino acids (e.g., Phe, Leu, Ile, Gly, ~al, Ala, etc.) may be used to present the peptides to binding sites with a variety of local environments.
Unless modified during or after synthesis by the translation machinery, recombinant peptide libraries consist of sequences of the 20 normal L-amino acids.
While the available structural diversity for such a library is large, additional diversity can be introduced by a variety of means, such as chemical modifications of the amino acids.
- For example, as one source of added diversity a peptide library of the invention can have its carboxy terminal amidated. Carboxy terminal amidation is necessary to the activity of many naturally occurring bioactive peptides. This modification occurs in vivo through cleavage of the N-C bond of a carboxy terminal Gly residue in a two-step reaction catalyzed by the enzyme~ peptidylglycine alpha-amidation monooxygenase ... . - - - . . . ........ . ~ ......... - -... . .

: -, . , ,: ., , .. .. : .: .
- . : ~

2 ~ ~J2 ~. d ~, i WO91/19818 PCT/US91/W~ _ (PAM) and hydroxyglycine aminotransferase (HGAT). See, Eipper et al., J. Biol. Chem. 266:7827-7833 (1991~;
Mizuno et al., Biochem. Biophys. Res. Comm. 137 (3): 984-991 (1986); Murthy et al., J. Biol. Chem. ~61 (4): 1815-1822 (1986); Katopodis et al., Biochemistry 29: 6115-6120 (l990); and Young and Tamburini, J. Am. Chem. Soc.
111: 1933-1934 (1989), each of which are .incorporated herein by reference.
Carboxy terminal amidation can be made to a peptide library of the invention which has the variable region exposed at the carboxy terminus. Amidation can be performed by treatment with enzymes, such as PAM and HGAT, in vivo or in vitro, and under conditions conducive to maintaining the structural integrity of the bioactive peptide. In a random peptide library of the present invention, amidation will occur on a library subset, - i.e., those peptides having a carboxy terminal Gly. A
library of peptides designed for amidation can be constructed by introducing a Gly codon at the end of the variable region domain of the library. After amidation, - an enriched library serves-as a particularly efficient source of ligands for receptors that preferentially bind amidated peptides.
Many of the C-terminus amidated bioactive peptides are processed from larger pro-hormones, where the amidated peptide is flanked at its C-terminus by the seguence -Gly-Lys-Arg-X... (where X is any amino acid).
In the present invention, oligonucleotides encoding the sequence -Gly-Lys-Arg-X-Stop are placed at the 3' end of the variable oligonucleotide region. When expressed, the Gly-Lys-Arg-X is removed by in vivo or in vitro enzymatic treatment and the peptide library is carboxy terminal amidated as described above.
Another means to add to the library diversity through carboxy terminal amidation involves the use of ` proteins that typically have an exposed C terminus, i.e., a protein that crosses a membrane with its carboxy :- - . :. . . -. . . . . . .

- - . ~ . : . , , , , , :.
- ' , . , . ~

W091/19818 2 0 3 d ~ ~ ~ PCT/US91/04~

terminus exposed on the extracellular side of the membrane. In this embodiment the variable oligonucleotides region, having a stop codon in the last position, is inserted in the 3' end of a sequence which encodes C terminus exposed protein, or at least a portion of the protein that is responsible for the C-terminus out orientation. The transferrin receptor protein is an example of one such protein. This receptor has been cloned and sequenced, as reported in McClelland et al., Cell 39:267-274 (1984), incorporated herein by reference.
An internal transmembrane segment of the transferrin receptor serves to orient the protein with its carboxy terminus out. When the cDNA is expressed, typically in eucaryotic cells, the random peptides are located extracellularly, having their amino terminus fused to the transferrin receptor and with a free carboxy terminus.
For carboxy terminal peptide libraries, a COS
cell expression cloning system can also be used and may be preferred in some circumstances. COS cells are transfected with a variable nucleotide library contained in an expression plasmid that replicates and produces mRNA extrachromosomally when transfected into COS cells.
Transfected cells bearing the random peptides are selected on immobilized ligand or cells which bear a binding protein, and the plasmid is isolated (rescued) from the selected cells. The plasmid is then amplified and used to transfect COS cells for a second round of screening. Because the random oligonucleotides are inserted directly into the expression plasmid, much larger libraries (i.e., total number of novel peptides) are constructed. Of course, for each round of panning the plasmid needs to be rescued from the COS cells, transfected into bacteria for amplification, re-isolated and tran~fected back into COS cells.
Other expression systems for carboxy terminal amidation of peptides of the invention can also be used.
For example, the variable oligonucleotide se~uences are 1 ~.

. . . . . - . . : . .: . . : : . ... . - : ~ :
- . .. , . ~, - : .. : ., , :, - .. . . . .
, ., ~ .. .. .. . .

WO91/19818 ~ PCT/US91/W~ _ inserted into the 3' end of, e.g~, the transferrin receptor cDNA contained in a baculovirus transfer vector.
Viral DNA and transfer vector are co-transfected into insect cells (e.g., Sf9 cells) which are used to propagate the virus in culture. When transferrin receptor is expressed, cells harboring recombinant virus, i.e., those producing the transferrin receptor/variable peptide fusion protein, are selected using an anti-transferrin receptor monoclonal antibody linked to a particle such as magnetic microspheres or other substance to facilitate separation. The selected cells ~re further propagated, allowed to lyse and release the library of recombinant extracellular budded virus into the media.
The library of recombinant virus is amplified (e.g., in Sf9 cells), and aliquots of the library stored.
Sf9 cells are then infected with the library of recombinant virus and panned on immobilized target receptor, where the panning is timed to occur with transferrin receptor expression. The selected cells are allowed to grow and lyse, and the supernatant used to ; infect new Sf9 cells, resulting in amplification of virus that encodes peptides binding to the target receptor.
After several rounds of panning and amplification, single viruses are cloned by a Sf9 cell plaque assay as described in Summers and Smith, A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Experiment Station ~ulletin No. 1555 (1988), incorporated herein by reference. DNA in the variable oligonucleotide insert region is then sequenced to determine the peptides which bind to the target receptor.
An advantage of the baculovirus system for peptide library screening is that expression of the transferrin receptor/random peptide fusion protein is very high (>l millions receptors per cell). A high expression level increases the likelihood of successful panning based on stoichiometry and/or contributes to . :, ~ -:

. . ; - .
.. . . . ..

W091/19818 2 ~ ~ 4 ~ ~ ~ PCT/US91/04~

polyvalent interactions with an immobilized target receptor. Another advantage of the baculovirus system is that, similar to the peptide on phage method, infectivity is exploited to amplify virus which is selected by the panning procedure. During the series of pannings, the DNA does not need to be isolated and used for subsequent transfections of cells.
Other expression systems can be employed in the present invention. As eucaryotic signal sequences are operable in yeast and bacteria, proteins with a carboxy terminus out orientation, such as the transferrin receptor, can be appropriately expressed and oriented in yeast or bacteria. The use of yeast or bacteria allows large libraries and avoids potential problems associated with amplification.
Other modifications found in naturally occurrin~ peptides and proteins can be introduced into the libraries to provide additional diversity and to contribute to a desired biological activity. For example, the variable region library can be provided with codons which code for amino acid residues involved in `Y phosphorylation, glycosylation, sulfation, isoprenylation (or the addition of other lipids), etc. Modifications not catalyzed by naturally occurring enzymes can be introduced by chemical means (under relatively mild conditions) or through the action of, e.g., catalytic antibodies and the like. In most cases, an efficient strategy for library construction involves specifying the enzyme (or chemical) substrate recognition site within or adjacent to the variable nucleotide region of the library so that most members of the library are modified. The substrate recognition site added could be simply a single residue (e.g., serine for phosphorylation~ or a complex consensus sequence, as desired. ~-Conformational constraints, or scaffolding, can also be introduced into the structure of the peptide libraries. A number of motifs from known protein and .

.

;:, , ,,., ~ ~ -~ .

WO91/t9818 2 ~ PCT/US91/~ _ peptide structures can be adapted for this purpose. The method involves introducing nucleotide sequences that code for conserved structural residues into or ~djacent to the variable nucleotide region so as to contribute to the desired peptide structure. Positions nonessential to ~he structure are allowed to vary.
A degenerate peptide library as described herein can incorporate the conserved frameworks to produce and~or identify members of families of bioactive peptides or their binding receptor elements. Several families of bioactive peptides are related by a secondary structure that results in a conserved "framework," which in some cases is a pair of cysteines that flank a string of variable residues. This results in the display of the variable xesidues in a loop closed by a disulfide bond, ; as discussed above.
In some cases a more complex framework is shared among members of a peptide family which contributes to the bioactivity of the peptides. An example of this class is the conotoxins, peptide toxins of lO to 30 amino acids produced by venomous molluscs known as predatory cone snails. The conotoxin peptides generally possess a high density of disulfide cross-` linking. Of those that are highly cross-linked, most ~elong to two groups, mu and omega, that have conserved primary frameworks as follows:
mu CC................ C..... .C..... CC; and ~^ omega C.............. C..... CC..... C..... C
The number af residues flanked by each pair of C's varies from 2 to 6 in the peptides reported to date. The side ; chains of the residues which flank the Cys residues are apparently not conserved in peptides with different specificity, as in peptides from different species with similar or identical specificities. Thus, the conotoxins have exploited a conserved, densely cross-linked motif as a framework for hypervariable regions to produce a huge .

. . .

~ . .
-: ' . . - . ' ' -; : .. .. . .

, WO91/19818 2 ~ i PCT/US91/04~W

array of peptides with many different pharmacological effects.
The mu and omega classes (with 6 C's) have 15 possible combinations of disulfide bonds. Usually only one of these conformations is the active ("correct") form. The correct folding of the peptides may be directed by a conserved 40 residue peptide that is cleaved from the N-terminus of the conopeptide to produce the small, mature bioactive peptides that appear in the venom.
- With 2 to 6 variable residue~ between each pair of C's, there are 125 (53) possible framework arrangements for the mu class (2,2,2, to 6~6,6), and 625 (54) possible for the omega (2,2,2,2 to 6,6,6,6). Randomizing the identity of the residues within each framework produces 101 to >103 peptides. "Cono-like" peptide libraries are constructed having a conserved disulfide framework, varied numbers of residues in each hypervariable region, and varied identity of those residues. Thus, a sequence for the structural framework for uSe in the present invention comprises Cys-Cys-Y-Cys-Y-Cys-Cys, or Cys-Y-; Cys-Y-Cys-Cys-Y-Cys-Y-Cys, wherein Y is (NNR)~ or (NNS)~, and where N is A, C, G or T, K is G or T, S is G or C, and x is from 2 to 6.
Other changes can be introduced to provide residues that contribute to the peptide structure, around ` which the variable amino acids are encoded by the library members. For example, these residues can provide for ~-helices, a helix-turn-helix structure, four helix ; 30 bundles, etc., as described.
; Another exemplary scaffold structure takes advantage of metal ion binding to conformationally constrain peptide structures. Properly spaced invariant ~etal ligands (cysteines and histidines) for certain di~alent cations (e.g., zinc, cobalt, nickel, cadmium, etc.) can be specifically incorporated into the peptide libraries. Depending on the particular motif ~pecified . .

.. .. . , .
.. . . , ., . : . ............ .
. . . . . . ..

wo 91/19818 2 ~ A, PCT/US91/~

these can result (in the case of zinc coordination, for example) in zinc loops, zinc fingers, zinc twists, or zinc clusters, as generally described in Berg (J. Biol.
Chem. 265:6513-6516 (1990)), Green et al. (Proc. Natl.
Acad. Sci. USA, 86:4047-4051 (1989)), Parraga et al.
(Science 241:1489-1492 (1988)), Regan et al. (Biochem., 29:10878-10883 (1990)), and Vallee et al. ~Proc. Natl.
Acad. Sci. USA, 88:999-1003 (1991)), each incorporated herein by reference. Other DNA binding peptides, such as those which correspond to the transcriptional transactivators referred to as leucine zippers, can also be used as a framework, where leucine residues are repeated every seven residues in the motifs, and the region is adjacent to an alpha helical region rich in lysines and arginines and characterized by a conserved helical face and a variable helical face.
Other specialized forms of structural constraints can also be used in the present invention.
For example, certain serine proteases are inhibited by small proteins of conserved structure (e.g., pancreatic trypsin inhibitor). This conserved framework can incorpZorate degenerate regions as described herein to generate libraries for screening for novel protease inhibitors.
In another aspect related to frameworks for a peptide library, infoxmation from the structure of known ligands can be used to find new peptide ligands having features modified from those of the known ligand. In this embodiment, fragments of a gene encoding a known ligand, prepared by, e.g., limited DNAse digestion into pieces of 20 to 100 base pairs, are subcloned into a variable nucleotide region system as described herein eit~er singly or in random combinations of several fragments. The fragment library is then screened in accordance with the procedures herein for binding to the receptor to identify small peptides capable of binding to the receptor and having characteristics which differ as . . .

. ~

, WO91/19818 2~ i i` PCT/US91/04 desired from the parental peptide ligand. This is useful for screening for any receptor-ligand interaction where one or both members are encoded by a gene~ e.g., growth factors, hormones, cytokines and the like, such as insulin, interleukins, insulin-like growth factor, etc.
The peptide-phage libraries of the present invention can also be used to determine the site specificity of enzymes that modify proteins, e.g., the cleavage specificity of a protease. For example, factor X cleaves after the sequence Ile-Glu-Gly-Arg. A library of variable region codons as described herein is constructed having the structure: signal sequence--variable region--Tyr-Gly-Gly-Phe-Leu--pIII. Phage from the library are then exposed to factor X~ and then panned on an antibody (e.g., 3E7), which is specific for N-terminally exposed Tyr-Gly-Gly-Phe-Leu. A pre-cleavage pannin~ step with 3E7 can be employed to eliminate clones cleaved by ~. coli proteases. Only members of the library with random sequences compatible with cleavage with factor X~ are isolated after panning, which sequences mimic the Ile-Glu-Gly-Arg site.
Another approach to protease substrate identification involves placing the variable region between the carrier protein and a reporter sequence that is used to immobilize the complex (e.g., Tyr-Gly-Gl~-Phe-Leu). Libraries are immobilized using a receptor that binds the reporter sequence (e.g., 3E7 anti~ody). Phage clones having sequences compatible with cleavage are released by treatment with the desired protease.
Some peptides, because of their size and/or sequence, may cause severe defects in the infectivity of --their carrier phage. This causes a loss of phage from the population during reinfection and amplification following each cycle of panning. To minimize problems associated with defective infectivity, DN~ prepared from the eluted phage is transformed into appropriate host cells, such as, e.g., E. coli, preferably by - . - - , - ...... . . . . . . . ...
. . . : ,, : , :, . ., : - . .
,: - :
, ,: , .

WO91/19818 2 ~ i PCT/USgl/04~

electroporation, as described in, for example, Dower et al., Nucl. Acids Res. 16:6127-6145 (1988), incorporated herein by reference, or by well known chemical means.
The cells are cultivated for a period of time sufficient for marker expression, and selection is applied as typically done for DNA transformation. The colonies are amplified, and phage harvested for affinity enrichment as described below. Phage identified in the affinity enrichment can be re-amplified in additional rounds o~
propagation by infection into appropriate hosts.
The successful transformants are typically selected by growth in a selective medium or under selective conditions, e.g., an appropriate antibiotic, which, in the case of the fd-tet vector, is preferably tetracycline. This may be done on solid or in liquid growth medium. For growth on solid medium, the cells are grown at a high density (_108 to 109 tfs per m2) on a large surface of, for example, L-agar containing the selective antibiotic to form essentially a confluent lawn. The cells and extruded phage are scraped from the ; surface and phage are prepared for first round of panning easentially as described by Parmley and Smith, Gene 73:305-318 (1988). For growth in liquid culture, cells may be grown in L-broth and antibiotic through about 10 or more doublings. The phage are harYested by standard procedures (see Sambrooke et al., Molecular Cloninq, 2nd ed. (1989), supra, for preparation of M13 phage) as described below. Growth in liquid culture may be more ` convenient because of the size of the libraries, while growth on solid media likely provides less chance of bias during the amplification process.
For affinity enrichment of desired clones, generally about 103 to 104 library equivalents (a library equivalent is one of each recombinant: 104 equivalents of a library of 109 members is 109 x 104 = 1ol3 phage), but typically at least lo2 library equivalents but up to about 105 to 106, are incubated with a receptor (or portion :' .

,. . . . . . . . ,. ~ . . : ~ . :

. .. .: ::- ' . : ,. . , . , : - .
.- :: :..... .. ' ..... . , ,, . :

WO 91/19818 PCI'/US91/04384 2 ~

thereof) to which the desired peptide is sought. The receptor is in one of several forms appropriate for affinity enrichment schemes. In one example the receptor is im~obilized on a surface or particle, and the library of phage bearing peptide is then panned on the immobilized receptor generally according to the procedure described below.
A second example of receptor presentation is receptor attached to a recognizable ligand (which may be attached via a tether). A specific example of such a ligand is biotin. The receptor, so modified, is incubated with the library of phage and binding occurs with both reactants in solution. The resulting complexes are then bound to streptavidin (or avidin) through the biotin moiety. The streptavidin may be immobilized on a surface such as a plastic plate or on particles, in which case the complexes ~ (phage/peptide/receptor/biotin/streptavidin) are ; physically retained; or the streptavidin may be labelled, ; 20 with a fluorophore, for example, to tag the active phage/peptide for detection and/or isolation by sorting procedures, e.g., on a fluorescence-activated cell sorter.
Phage which express peptides without the desired specificity are removed by washing. The degree and stringency of washing required will be determined for each receptor/peptide of interest. A certain degree of control can be exerted over the binding characteristics of the peptides recovered by adjusting the conditions of the binding incubation and the subsequent washing. The -~ temperature, pH, ionic strength, divalent cation concentration, and the volume and duration of the washi~g will select for peptides within particular ranges of affinity for the receptor. Selection based on slow dissociation rate, which is usually predicti~e of high affinity, is the most practical route. This may be done either by continued incubation in the presence of a -.

... . . . . . . . . . . :
: - . . . ~ .
- , . . .. , ~ :

- : , ... . . ....
.. . : , . . . : ~ : ~ , - .; . - . . :. . .: :

2 ~ i. .L
WO 91/19818 PCr/US91/04384 saturating amount of free ligand, or by increasing the volume, number, and length of the washes. In each case, the rebinding of dissociated peptide-phage is prevented, and with increasing time, peptide-phage of higher and S higher affinity are recovered. Additional modifications of the binding and washing procedures may be applied to find peptides which bind receptors under special conditions.
Although the phage screening me~hod is highly specific, the procedure generally does not discriminate between peptides of modest affinity (micromolar dissociation constants) and those of high affinity (nanomolar dissociation constants or greater). The ability to select phage bearing peptides with relatively low affinity may be result of multivalent interaction between a phage/peptide particle and a receptor. For instance, when the receptor is an IgG antibody, each phage bearing peptides may bind to more than o~e antibody binding site, either by a single phage binding to both sites of single IgG molecule or by forming network o~
phage-IgG, which multivalent interaction produces a high avidity and tenacious adherence of the phage during washin~.
To enrich for the highest affinity peptide ligands, a substantially monovalent interaction between phage and the receptor (typically immobilized on a solid-phase) may thus be appropriate. The screening (selection) with substantially monovalent interaction can be repeated as part of additional rounds of amplification and selection of bacteriophage. Thus, under these circumstances the receptor molecule is substantially monovalent, such as the Fab binding fragment of an antibody molecule.
A strategy employing a combination of conditions favoring multivalent or monovalent interactions can be used to advantage in producing new peptide ligands for receptor molecules. By conducting .. , .
. . . ...

WO91/19818 2 a 3 ~Li~1 PCT/US91/04 the first rounds of screening under conditions to promote multivalent interactions, high stringency washing can be used to greatly reduce the background of non-specifically bound phage. This high avidity step may select a large pool or peptides with a wide range of affinities, including those with relatively low affinity. It may select for specific recognition kernels, such as the Tyr-Gly dipeptide described in the examples below.
Subsequent screening under conditions favoring increasingly monovalent interactions and isolation of phage based on a slow dissociation rate may then allow the identification of the highest affinity peptides.
Monovalent interactions may be achieved by employing low concentrations of receptor (for example, from about l to lO0 pM).
It ~hould be noted that, as an aspect of the present invention, determining a dissociation rate for a peptide of interest and the selected receptor molecule - under substantially monovalent conditions allows one to extrapolate the binding affinity of the peptide for the receptor. This procedure avoids the necessity and inconvenience of separately determining binding affinities for a selected peptide, which could be especially burdensome if a large number of peptides have been selected.
once a peptide sequence that imparts some affinity and specificity for the receptor molecule is known, the diversity around this "recognition kernel" may be embellished. For instance, variable peptide regions ! 30 ~ay be placed on one or both ends of the identified sequence. The known sequence may be identified from the literature, as in the case of Arg-Gly-Asp and the integrin family of receptors, for example, as described in Ruoslahti ~nd Pierschbacher, Science 238:491-497 (1987), or may be derived from early rounds of panning in the context of the present invention.

- . . . ,- .:

.

-. . , : . . . - : , .. .

WO91/19818 2 ~ i PCT/US91/04~ _ Libraries of peptides on phage produced and screened according to the present invention are particularly useful for mapping antibody epitopes. The ability to sample a large number of potential epitopes as described herein has clear advantages over the methods based on chemical synthesis now in use and described in, among others, Geysen et al., J. Immunol. Meth. 102:259-274 (1987). In addition, these libraries are useful in providing new ligands for important binding molecules, such as hormone receptors, adhesion molecules, enz~mes, and the like.
Accordingly, the following examples are offered by way of illustration, not by way of limitation.
EXAMPLE I

Reagents and Strains BstXI restriction endonuclease, T4 DNA ligase, and T4 kinase were obtained from New England Biolabs.
Streptavidin and biotinylated goat anti-mouse IgG were obtained from BRL. Sequenase 2.0 was obtained from U.S.
Biochemical. Monoclonal antibody 3E7 used in initial studies was provided by A. Herz and is described in Meo et al., infra., incorporated herein by reference, and was also purchased from Gramsch Laboratories (Schwabhausen, West Germany). tl25I-tyr28]b-endorphin (2000 Ci/mmol) was purchased from Amersham Corp. (Arlington Heights, IL).
Oligonucleotides were synthesized with an Applied BioSystems PCR-Mate and purified on OPC columns (ABI).
Peptides were synthesized with an Applied BioSystems 431A
(Foster City, CA) or Biosearch model 9600 (San Rafael, CA) synthesizer and purified to greater than 95~ purity by reverse phage HPLC. Peptide content of the pure peptides was determined by amino acid analysis and the composition was verified by FAB-MS. Bacteriophage fd-tet and E. coli K9l were provided by G. Smith, Univ. of Missouri, Columbia, MO 652ll, and are described in, among .. . . . . .. ..
- . -, :. ., . - -- . . . . ... .
.. . .

, . - , . . , . : ~ . ~

WO91/19818 2~ 3~ ~ ; PCTtUS91/~

others, Zacher et al., Gene 9:127-140 (1980), Smith et al., Science 228:1315-1317 t1985) and Parmley and Smith, Gene 73:305-318 (1988).

Construction of Vector fAFF1 A filamentous bacteriophage vector was constructed from the tetracycline resistance transducing vector fdTet, described in Zacher et al., supra. The vector, designated fAFFl, was designed to provide many choices in the size and location of the peptides expressed fused to the pIII bacteriophage coat protein.
pIII is made as a preprotein with an 18 amino acid leader sequence that directs pIII to the inner membrane of the bacterial host cell before it becomes assembled into an intact phage particle (Goldsmith and Konigsberg, Biochem.
16:2686-2694 (1977) and Boeke and Model, Proc. Natl.
Acad. Sci. U5A 79:5200-5204 (1982) incorporated herein by reference). As explained further below, a peptide library was constructed by cloning an oligonucleotide of the structure shown in Fig. lB to place the variable hexapeptide region at the N-terminus of the processed ; protein. These first six residues are followed by two glycines and then the normal sequence of pIII. The library consists of about 3 x 108 independent recombinants.
; A cloning site, consisting of two non-complementary BstXI sites, was engineered into the 5'-region of gene III. As shown in Fig. lA, two non-complementary BstXI sites flank the region encoding amino acids surrounding the signal peptidase site (the N-terminus of the mature pIII). fAFFl also has a -1 frameshift mutation in pIII that results in non-infective phage. By removing the BstXI fragment and inserting an ` oligonucleotide of the appropriate structure, (a) 3S portions of the removed sequence can be precisely reconstructed (the correct signal peptide site, for example,) (b) one or more additional amino acids may be . ~:

,. . . , ,~, . -, :.

WO91/19818 2 i) ~ PCT/US9l/~ _ expressed at several locations, and (c) the correct translation frame is restored to produce active, infective pIII.
Construction of the cloning site at the 5'-region of gene III was accomplished by first removing a BstXI restriction site already present in the TN10 region of fdTet, RF DNA was digested with BstXI restriction endonuclease, and T4 DNA polymerase was added to remove the protruding 3' termini. Blunt-ended molecules were then ligated and transformed into MC1061 cells. RF DNA
isolated from several tetracycline resistant transformants was digested again with BstXI; a clone that was not cleaved was selected for construction of the double BstXI site. Site-directed mutagenesis (Kunkel et al., Meth. Enzymol. 154:367-382 (1987), incorporated by reference herein) was carried out with th~
oligonucleotide 5'-TAT GAG GTT TTG CCA GAC AAC TGG AAC
AGT TTC AGC GGA GTG CCA GTA GAA TGG AAC AAC TAA AGG.
Insertion of the correct mutagenic sequence was confirmed ` 20 by dideoxy sequencing of RF DNA isolated from several tetracycline-resistant transformants.

Construction of a Diverse Oliaonucleotide Library Oligonucleotides which were cloned have the general structure shown in Fig. lB. The 5' and 3' ends have a fixed seguence, chosen to reconstruct the amino acid sequence in the vicinity of the signal peptidase site. The central portion contained the variable regions which comprise the oligonucleotide library members, and may also code for spacer residues on either or both sides of the variable sequence.
A collection of oligonucleotides encoding all possible hexapeptides was synthesized with the sequence 5'-C TCT CAC TCC (NNK)6 GGC GGC ACT GTT GAA AGT TGT-3'.
N was A, C, G, and T (nominally equimolar), and K was G
- and T (nominally equimolar). This sequence, designated ON-49, was ligated into the BstXI sites of fAFFl after '' ' . ,"

: : . ^ ', . . , ~ . '. .
. - ~ . . . .
, . .

WO 91tl9818 2 ~ PCT/US91/04 annealing to two "half-site" oligonucleotides, ON-28 (5'-GGA GTG AGA GTA GA-3') and ON-29 (5'-CTT TCA ACA GT-3'), which are complementary to the 5'- and 3'- portions of ON-49, respectively. "Half-site" oligonucleotides anneal to the 5'- and 3'- ends of oligonucleotide ON-49 to form appropriate BstXI cohesive ends. This left the appropriate BstXI site exposed without the need to digest with BstXI, thus avoiding the cutting of any BstXI sites that might have appeared in the varia~le region. The vector fAFFl (100 ~g) was digested to completion with BstXI, heat inactivated at 65-C, and ethanol precipitated twice in the presence of 2 M ammonium acetate.
Oligonucleotides-were phosphorylated with T4 kinase, and - annealed in 20 mM Tris-HCl, pH 7.5, 2 mM MgCl2, 50 mM
- 15 NaCl, by mixing 1.5 ~g ON-28, 1.2 ~g ON-29, and 0.5 ~g : ON-49 with 20 ~g BstXI-digested fAFF1 RF DNA, heating to 65-C for 5 minutes and allowing the mixture to cool slowly to room temperature. This represented an approximate molar ratio of 1:5:100:100 (fAFF1 vector: ON-49: ON-28: ON-29). The annealed structure is then - ligated to BstXI-cut fAFFl RF DNA to produce a double-stranded circular molecule with a small, single stranded gap. These molecules may be transformed into host cells.
The annealed DNA was ligated in 20 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 2 mM DTT, 1 mM ATP, by the addition of 20 units of T4 DNA ligase and incubated overnight at 15-C.
Alternatively, before transformation, the gap may be filled-in under conditions disfavoring secondary structure in the variable region. In some experiments the gapped circular structure created by this ligation was filled in with T4 DNA polymerase in the presence of ligase and dNTPs t400 ~M each) to produce a covalently closed, double-stranded molecule (Kunkel et al., supra).
The ligated DNA was ethanol precipitated in the presence of 0.3 M sodium acetate, resuspended in water, and transformed by electroporation into MC1061. Five electro-transformations, each containing ~0 ~1 of cells ~,. . ..
- .

. , . , . . :
: , : ~ . . : ., :- .. .. , . : - .
- .. . . .

WO91/19818 PCT/US91/~
2 ~ L~

and 4 ~g of DNA (50 ~g/ml), were performed by pulsing at 12.5 kV/cm for 5 msec as described in Dower et al., Nucleic Acids Res. 16:6127-6145 (1988), incorporated by reference herein. After one hour of non-selective outgrowth at 37-c in 2 ml of SOC medium (2% Bacto tryptone, 0.5% Bacto yeast extract, 10 mM NaCl, 2.5 mM
KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose; see Hanahan, J. Mol Biol. 166:557-580 (1983)), the transformations were pooled, an aliquot was removed, and several dilutions were plated on LB agar plates containing tetracycline (20 ~g/ml) to assess the transformation efficiency. The remainder was used to inoculate one liter of L-broth containing tetracycline (20 ~g/ml) and was grown through approximately 10 doublings at 37-C to lS amplify the library.

Isolation of Phage Phage from liquid cultures were obtained by clearing the supernatant twice by centrifugation (8000 RPM for 10 min in JA10 rotor, at 4-), and precipitating phage particles with polyethylene glycol (final concentration 3.3% polyethylene glycol-8000, 0.4 M NaCl), and centrifuged as described above. Phage pellets were resuspended in TBS (50 mM Tris-HCl, pH 7.5, 150 mM NaCl) and stored at 4-C. In some cases, phage were isolated from plate stocks by scraping from the agar surface, resuspending in L-broth, and purifying as described above.

~ffinity Purification Approximately 103 to 104 library equivalents of ~ -phage were reacted overnight with 1 ~g of purified antibody in 1 ml TBS at 4-C. (Under these conditions, phage and antibody are about equimolar: therefore, antibody is in great excess over the phage ligand peptides.) Phage expressing peptides with affinity for mAb3E7 were isolated by a modificatlon of the procedure . .

.
- . . . , .

2 ~ 3 ~ L~
WO91/19818 PCT~US91~04~W

of Parmley and Smith, supra. A 60 x 15 mm polystyrene petri plate was coated with l ml of streptavidin solution (l mg/ml streptavidin in O.l M NaHC03, pH 8.6, 0.02% NaN3) and incubated overnight at 4-C. The streptavidin solution was removed the following day. The plate was filled with lO ml blocking solution (30 mg/ml BSA, 3 ~g/ml streptavidin in O.l M NaHC03, pH 9.2, 0.02% NaN3) and incubated for two hours at room temperature.
Biotinylated goat anti-mouse IgG (2 ~g) was added to the - 10 antibody-reacted phage library and incubated for two hours at 4-C. Immediately before panning, the blocking solution was removed from the streptavidin-coated plate, and the plate was washed 3 times with TBS/0.05% Tween 20.
The antibody-reacted phage library was then added to the plate and incubated for 30 min. at room temperature. The phage solution was removed and the plate was washed ten times with lO ml TBS/0.05% Tween 20 over a period of 60 min. at room temperature. Adherent phage were removed by ; adding 800 ~l of elution buffer (l mg/ml BSA in O.l N HCl - 20 adjusted to pH 2.2 with glycine) to the petri plate and incubating for lO min. to dissociate the immune complexes. The eluate was removed, neutralized by addition of 45 ~l of 2 M Tris base, and used to infect log phase E. coli K9l cells.
The infected cells were then plated on LB agar plates containing tetracycline (20 ~g/ml), and grown overnight at 37-C. Phage were isolated from these plates - as described above and the affinity purification process was repeated for two more rounds. After each round of panning and amplification, DNA of phage from severaI
thousand colonies was pooled and sequenced to estimate the diversity in the cloning site. In the first two positions of each codon, bands of about the same intensity appeared in each lane, indicating the expected distribution of bases in these positions. In the third position of each codon the G band was somewhat more intense than the T band.

.

, . . : . . ` :.. : :: : . : .

- , . . . .

, ~
, . , ., : . , ~, : :

WO91/19818 2 ~ PCT/US91/n4~ _ After the final round of panning and amplification, a portion of the eluate was used to infect cells that were plated at low density on LB tetracycline plates. To analyze the diversity of peptide sequences in the library in a more direct way, we picked 52 individual colonies producing infectious phage, and sequenced the DNA of their variable regions. Individual colonies were picked and transferred to culture tubes containing 2 ml LB tetracycline and grown to saturation. Phage DNA was isolated and then sequenced by a method designed for the - Beckman Biomek Workstation employing 96-well microtiter plates (Mardis and Roe, Biotechniques 7:840-850 (1989~, incorporated by reference herein). Sinqle stranded DNA
was sequenced using Sequenase 2.0 and an oligonucleotide sequencing primer (5'-CGA TCT AAA GTT TTG TCG TCT-3 ' ) which is complementary to the sequence located 40 nucleotides to the 3 ' side of the second BstXI site in fAFFl.
The distribution of bases at each position within each codo~ is given in Table 1. The first two positions of each codon have close to the expected equimolar distribution of the four bases. The third position is significantly biased, containing about 50% `
more G than T in this sample. This bias is most likely ~-introduced during the chemical synthesis of the oliqonucleotide mixture, but may also reflect biological biases i~posed on the expressed peptides.
:
. .

;~
, .

.

., .: . : . ., - . , . . - .

WO91/1~818 ~ PCT/US91/04 .
.
Table l: Nucleotide Distribution in the Diversity Region of Infectious Phage Randomly Selected from the Library.
Frequency of each base by position in codon (%) N N K

A 22 22 <l .

.

In Fig. 2, the amino acid sequences are listed for the peptides encoded by the oligonucleotide inserts of a sample of randomly selected, infectious phage. The amino acid content of the expressed peptides from the 52 randomly selected infectious phage appears in Table 2.

.~ .
.
'~

, .
., .
., . ..
., .

- , . , ~ ~ . . :, " ' : - ' ~ : . . . .

WO91~19818 ~ PCT/USgl/04 Table 2: Amino Acid Content in the Variable Peptide of 52 Randomly-Selected Infectious Phage Amino Nominal Nominal Observed Obs/Nom Acid FrequencyOccurrenceOccurrence A 0.065 l9 27 1.42 C 0.032 9 8 0.89 D 0.032 9 10 15 1.11 E 0.032 9 9 1.00 F 0.032 9 12 1.33 - G 0.065 19 33 1.74 H 0.032 9 7 . 0.78 I 0.032 9 6 : 0.67 K 0.032 9 16 1.78 L 0.097 28 35 30 1.25 :, .; M 0.032 9 10 :: 1.11 N 0.032 9 7 350.78 - P 0.065 19 9 -~ 0.47 : Q 0.032 9 15 `. 1.67 R 0.097 28 29 1.04 S 0.097 28 30 1.07 T 0.065 19 14 0.74 V 0.065 19 18 ` 0.95 - W 0.032 9 11 : 501.22 Y 0.032 9 6 0.67 ..

', 55 ~ :
. .
., .
: . . . ~ . ~ . : - : :.:.. . ... . . . . , - . . . : . .- , : .
- . : - . . . , ~ , .. ... - ... ... .

WO91/19818 2 ~ PCT/US91/W~

As shown in Table 2, the ratio of the observed occurrence of each amino acid to that exp~cted on the basis of codon frequency ranges from about 0.5 to 2, - 5 consistent with a random distribution of sequences.
Constructing a library of peptides displayed on the N-terminus of processed pIII necessarily alters amino acids in the vicinity of the siynal peptidase cleavage site. Certain changes in the corresponding region of the major coat protein, pVIII, have been shown to reduce processing efficiency, slowing or preventing the incoxporation of pVIII to virions. If pIII were similarly affected, the diversity of peptides contained in the library would be reduced. The finding that most amino acids appear at each position of the variable peptides of randomly selected phage indicates that processing defects do not impose severe constraints on the diversity of the library.
Isolation and se~uencing of phaae havina hiqh avidity for anti-b-endor~hin antibodv.
Nonoclonal antibody 3E7 binds to B-endorphin and, like the ~-opioid receptor, recognizes the N-terminal portion of the protein (Tyr-Gly-Gly-Phe), which is present on most natural opioid peptides. The antibody also binds tightly to leu- and met-enkephalin (YGGFL, YGGFM), and a variety of related opioid peptides (Meo et al., Proc.jNatl. Acad. Sci. USA 80:4084-4088 (~983), Herz ~` et al., Life Sciences 31:1721-1724 (1982), and Gramsch et al., J. Neurochem. 40:1220-1226 (1983). The N-terminal ~` 30 hexapeptide library was screened against 3E7 by carrying out three rounds of panning~ elution, and amplification.
The recoveries of phage from this process are shown in Table 3. In each round the proportion of phage adsorbed to the antibody increased by about 100-fold, and in the last round, o~er 30% of the input phage were recovered.
~hese results indicated that phage were pxeferentially nriched in each panning step.

WO gl/19818 ~ ~ 8 ~ PCT/US91/04~

Table 3: Recovery o Phage from Panning on mAb3E7 Rounds of Input of Eluted 5Recovery Panning Phage Phage Input/Eluted 4 . 0 X 1011 1 . 9 X 107 4 . 8 X

32 2.0 x lOll 5.0 x lOa 2.5 x 3 l.8 x lo10 5.6 x lO9 3.l x lo-l After each round of panning, DNA representing several thousand eluted phage was pooled and sequenced.
The area of the sequencing gel corresponding to the insertion site in gene III is shown in Fig. 3. The codon ; TCC specifying the serine that precedes the variable region is indicated by an arrow. After the first round of panning, the codon following this serine was clearly enriched in TAT (the single codon for tyrosine). After the second round, virtually all first codons in the pooled DNA appeared to be TAT. The second codons are ~; strongly GGK (the two codons for glycine). After three rounds of panning, it appeared that phage containing relatively few kinds of amino acids in the first four positions had been selected, whereas the fifth and sixth positions appeared to be as diverse as those in the starting phage population.
The DNA samples from 51 individual phage i recovered from the third panning were sequenced. The ; deduced amino acid sequences of the N-ter~inal hexapeptides are shown in Fig. 4 and the amino acid distributions of these peptides are summarized in Table 4. Each of the 51 panned phages analyzed had an N-terminal tyrosine, and nearly all (94%) had a glycine in the second position. The third position in our sample is occupied by many amino acids, some of which are present : -~, ~

' ,.' ' ' . ', . ... ' .,., . , ' , . ~ . ~
, ' ~ . ' , ~ ' . . . . ' ,... . ~ . ' ''.' , ",, , , . ' ' ' ' ' , , . ' '' ' ' ' , ' ~ . "

.' " ' . ' ' ' . ' .~." ' ' ' '. ' ' ,~ ,. " ' ''' ' '. . ' WO91/19818 PCT/US91/04~
2~3~

more often than would be expected by chance. The fourth position is occupied primarily by-the large aromatic residues Trp and Phe (together 50%), and the bulky hydrophobic residues Leu and Ile (an additional 45%).
The fifth and sixth positions contain essentially random distributions of amino acids, with only alanine appearing at slightly greater than chance in position five.

Table 4: Distribution of Amino Acids in the Diversity Peptide of 51 Phage Selected by Panning With Anti-endorphin Antibody ~~
Residue Amino Nominal Observed Enrichment~ A ~
Po-ition Acid Frequency Frequency Ratio -~
: 1 Y.031 1.00 33 . 2 G.062 0.94 :16 A,S <1 ~ 25 : 3 G.062 0.31 5 W.031 0.10 3 -. S .093 0.21 2 : A .062 0.12 2 . 30 N .031 0.06 2 D,E,F,K, <1 L,M,P,T,V
: 4 W .031 0.31 . 10 . 35 F .031 0.19 6 L .093 0.35 4 I .031 0.10 3 A,G,M <1 40a. Obsërved frequency divided by nominal frequency.

, EXAMPLE II
- Binding Affinities of Peptides -for Receptor Monoclonal Antibody 3E7 , .

: : . . . : . . : .

WO91/l9818 PCT/US91/n4~
2 0 ~

The affinity of peptides for the 3E7 antibody has been previously determined for those peptides related to naturally-occurring opioid peptides. Meo et al., supra. As none of the peptides identified by the procedure described herein had been previously described, six of these peptides were chemically synthesized and their binding affinities estimated.
The peptides were synthesized according to well known protocols, as described in, for example, Merrifield, Science 232:341-347 (1986), incorporated by reference herein. A solution radioimmunoassay was used to estimate the binding affinities of peptides for mAb 3E7. Solution radioimmunoassay using [125I]b-endorphin (20,000 cpm) and purified 3E7 antibody (0.25 ~g/ml) was conducted as described by Meo et al., su~ra, with the exception that the final volume was 150 ~l. Antibody-bound and free [125I]b-endorphin were separated by addition of activated charcoal followed by centrifugation, as described in Ghazarassian et al., Life Sciences 27:75-86 (1980). Antibody-bound ~125I]b-endorphin in the supernatant was measured in a gamma counter. For each peptide, inhibition of tl25I]b-endorphin was determined at six different concentrations at 1/3 log unit intervals and the 50% inhibitory concentration (IC50) was determined by fitting the data to a two-parameter logistic equation using the ALLFIT
; program, as described in DeLean et al., Am. J. Physiol.
235:E97-E102 (1978).
The previously reported high degree of specificity of the 3E7 antibody for the intact N-terminal epitope Tyr-Gly-Gly-Phe which is common to naturally occurring opioid peptides. Meo et al., supra, was verified. Removal of Tyr or deletion of any of the amino acids of the sequence Tyr-Gly-Gly-Phe-Leu had deleterious effect on binding affinity (Table 5).

~,' .
. ~ .
.. ..... . . .. .
,, : . . .. ...

' WO91/19818 PCT/US91/04~
t :L

Shown in Table 5 are the IC50 for the six peptides which were identified by the phage panning method and chemically synthesized. Under the conditions of the radioimmunoassay (30 pM [l25I]b-endorphin; 20%
tracer bound; 18 hr. incubation), the IC50 should be very close to the dissociation constant (Kd) for the peptideO
The peptides are all relatively low affinity compared to YGGFL, with IC50's ranging from 0.35 to 8.3 ~M.

Table 5: Relative affinities of peptides for 3E7 antibody determined by solution radioimmunoassay. a Affinity Peptide N IC50 (~M) Relative to YGGFL
YGGFL (6) 0.0071 (0.0054,0.0093) YGGF (3) 0.19 (0.093,0.38) 0.037 YGGL (3) 3.8 (2.1,6.6) 0.0018 YGFL (3) 28 (17,47) 0.00025 YGG (2) >1000 <0.0000071 GGFL (2) >1000 <0.0000071 ; GGF (2) >1000 <0.0000071 GFL (2) >1000 <0.0000071 YGFWGM (3) 0.35 (0.19,0.63) 0.020 YGPFWS (3) 1.9 (1.3,2.8) 0.0037 ~- 30 YGGFPD (3) 2.3 (1.4,3.7) 0.0031 YGGWAG (3) 7.8 (6.0,10) 0.00091 YGNWTY (3) 7.8 (4.0,15) 0.00091 YAGFAQ (3) 8.3 (3.8,18) 0.00086 = Data are geometric means and 95% confidence intervals (calculated from S.E.M. of log IC50) from the number (N) of independent determinations indicated.
The data indicate that although the phage panning method is highly specific in that no unrelated peptides were selected, the procedure apparently does not discriminate between those of moderate (~M Kd) and high (nM Kd) affinity. The six peptides chosen from among the 51 clones that were se~uenced were only a small subset of those which were selected by three rounds of panning.
Based on their structural diversity, the phage library .

.:
, 2~$~

should contain thousands of different peptides with dissociation constants that are ~M or lower.
~he panning procedure we have utilized employs extensive washing to remove non-specifically bound phage.
Binding experiments with mAb 3E7 and [ H]YGGFL indicate a rapid dissociation rate, approximately t~=45 seconds at room temperature. Therefore, the ability to select phage ; bearing peptides with relatively low affinities may be the result of multivalent interaction between phage and antibody, as each phage typically has up to 4 or 5 copies of the pIII protein and each protein may carry a foreign peptide from the phage library.

EXAMPLE III
; Selective Enrichment and Characterization of Hiqh Affinity Ligands from Collections of Random Peptides on Phaae Phage bearing peptides YGGFL and YAGFAQ served as models to determine the effect of IgG and Fab concentration on the binding and recovery of phage bearing high (nM Kd) and low (~M Kd) affinity peptides.
; 25 To determine the effect of polyvalency, a phage sandwich ELISA was developed which used polyclonal anti-phage antibodies to detect bound phage. Purified monoclonal antibody 3E7 was used as intact IgG and as Fab fragments (produced uslng a commercially available kit ; 30 (Pierce), and biotinylated Fab fragments ~Gramsch Laboratories). No IgG was detected in Fab preparations when they were run on SDS-PAGE gels and stained with Coomassie blue. Fab was iodinated by reacting 5~g of Fab in 20 ~l of O.lM borate buffer (pH 8.5) with 250 ~Ci of t125I]Bolton-Hunter reagent (Amersham) for 3 hours and then purified by gel filtration on Sephadex G2S. After .

... , , . . ~ , :~ ............... , - , :. ::

WO 91/19818 PCI'/US91/04384 2 ~

purification, the specific activity of the [l25]FAB was approximately 15 ~Ci/~g.
Antisera were raised against phage particles lacking pIII fAFF1, which, as described above, contains a frameshift in the 5' end of gene III and i~ produced as non-infective polyphage. Cells from a two liter culture of E. coli K91 were removed by centrifugation and media was mixed with 400 ml of 20~ PEG in 0.5M NaCl. After incubation for 1 hr at 4 C. precipitated phage were isolated by centrifugation at 8500 rpm. The pellet was resuspended in TBS (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) and then ultracentrifuged in a SW50 rotor at a 42,000 rpm for 3 hrs. The resulting pellet was resuspended in water and the concentration of phage was estimated according to the method of Day, J. Mol. Biol. 39:265 (1969).
Three rabbits were injected intramuscularly with 0.5 mg of phage in Freunds complete adjuvant and then boosted with 0.25 mg of phage in incomplete adjuvant at 3 week intervals. The titer of the sera was measured with an ELISA using phage immobilized in Immulon 2 microtiter wells as described above. All rabbits ; produced high titer sera after the second boost. Sera collected after the third boost from one of the rabbits was used for the assays.
Antibodies reacting with phage were affinity purified as follows. Phage expressing native pIII (Fd-. tet) from a two liter culture were isolated (described above) and added to 20 ml of sera that was diluted 4-fold with PBS (10 mM sodium phosphate, 150 mM NaCl, pH 7.4).
- 30 After incubation for 2 hr at room temperature, phage/antibody complex was isolated by centrifugation for l 1 hr at 120,000 x g. The pellet was washed with 10 ml of PBS and centrifuged again. The final pellet was ; resuspended in 10 ml of 100 mM sodium acetate buffer pH
2.5 and incubated for 10 min. at room temp. The sample was subjected to same centrifugation and the resulting supernatant was neutralized with NaOH. IgG was then , :, . . .

'~' : .

:, . . . .

WO91/19818 ~ ~ PCT/US91/~

isolated using Protein-A agarose (Pierce) according to the manufacturer's instructions. The IgG was conjugated to alkaline phosphatase using a commercia'ly available kit (Pierce).
The phage sandwich ELISAs were performed as follows. Microtiter wells were incubated with lO0 ~g/ml of streptavidin for l hr at 37 C, then blocked with 200 ~l of PBS /0.1% bovine serum albumin (BSA~ for l hr.
Biotinylated IgG (0.5 ~g/ml) or biotinylated Fab (5 ~g/ml) (lO0 ml in PBS/O.l~ BSA) was added to the wells and incubated for an additional l hr at room temperature.
Preliminary studies in which immobilized IgG or Fab was detected with goat anti-mouse IgG conjugated to alkaline phosphatase indicated that these conditions maximally saturated the well with IgG or Fab. The difference in concentration for biotinylated IgG and Fab required for saturation of the streptavidin probably reflected differences in the fraction of the protein that was biotinylated.
After washing the wells with PBS, 50 ~l of PBS~0.1% BSA/0.05% Tween 20 or the same buffer containing , 200 ~M YGGFL free peptide was added to the well and incubated for 20 min at room temperature. Phage (101 infectious particles in 50 ~l PBS/0.1% BSA/0.05 Tween 20) bearing the peptides YGGFL or YAGFAQ were added and incubated for 18 hr at 4 C. After washing with TBS~0.05%
Tween 20, alkaline phosphatase anti-phage antibody (lO0 ~l of l:lO0 dilution) was added and incubated for l hr.
at room temperature. After washing with TBS/0.05~ Tween 20, lO0 ~l of alkaline phosphatase substrate (SIGMA~ in diethanolamine buffer (pH 9.5) was added and the absorbance at 405 nm was measured lO min. later.
Shown in Fig. 5 are the results of this assay when either biotinylated IgG or Fab was immobilized at maximal density on streptavidin coated wells. Specific binding was detected for both YGGFL- and YAGFAQ-phage;
the data indicate that the amount of binding did not : . - . . . . . . . . . . .. . .. .. .

WO91/1~818 2 0 ~ i PCT/US91/~

differ when IgG and Fab were used. In combination with the ~ata on monovalent dissociation rates of these peptides (see below), this suggests that antibody binding sites for both IgG and Fab are in sufficient proximity to one another to allow simultaneous binding of more than one of the peptides expressed by each phage particle.
The phage sandwich assay can also be used to determine the specificity and competitive nature of the interaction of peptide-bearing phage with immobilized antibody. In practice, an important aspect of the use of peptide on phage libraries is the characterization of individual phage isolates after sequential rounds of the affinity purification. Isolated phage may bind to other components found on an immobilizing surface, or may bind to the protein target at sites other than the active site. Using the phage sandwich assay, the binding of YGGFL- and YAGFAQ-phage was shown to be specific for the antibody and the interaction of the phage with antibody could be blocked by free YGGFL peptide.
Shown in Fig. 6 are the results of tests on the effect of Fab concentration and wash time on the recoveries of YGGFL- and YAGFAQ-phage. Microtiter wells were coated with streptavidin as described above. lOll infectious phage particles bearing the peptides YGGFL or YAGFAQ were incubated overnight at 4-C with either 50 ~l of 5nM or 50 pM biotinylated Fab. Aliquots were then added to different microtiter wells and incubated for l - hr. at room temperature. All the wells were washed quickly with TBS/0.05% Tween 20, with the last 200 ~l wash being le~t in the well. At various times - thereafter, wells washed quickly with TBS/0.05% Tween and the phage remaining bound were eluted with O.l M HCl (pH
adjusted to 2.2 with glycine) and quantitated by titering as described above.
The results indicate that low Fab concentration (50pM) and dissociation times greater than 30 minutes allowed the selective recovery of phage bearing the "
'~

- : . . : , .:: . . - . . . - . , W091/19818 2 ~ ~ 3~ PCT/US91/04 higher affinity peptide YGGFL. The use of a high concentration of Fab (5 nM) did not allow the discrimination of phage bearing high and low affinity peptides.
Phage enrichment using a low_concentration of biotinylated 3E7 Fab.
A pool of phage previously isolated by three rounds of panning and amplification using 5 nM 3E7 IgG
served as starting material for additional affinity purification and amplification using a modification of the previous protocol. Phage (loll infectious particles in l ml of TBS) were incubated overnight at 4-C with 2 ng of biotinylated Fab (50 pM final concentration). The mixture was then exposed to strep~avidin-coated plates and bound phage were isolated as described above.
Individual phage clones were then isolated and DNA was sequenced as described in Example I above.
Shown in Table 6 are the sequences of peptide inserts of phage that were isolated by 2 rounds of affinity isolation and amplification using 50 pM of biotinylated Fab. A notable difference between the seguences shown in Table 5 and those identified in Example II using three rounds of affinity purification with 50 nM IgG, is the frequency of Phe in the fourth position: 13/19 vs. lO/51 ~p~0.05 Fisher Exact Test).
Thus, the sequences more hiqhly resemble ~he known high a~finity peptides YGGFL and YGGFM. The sequence YGGFLT
was isolated ~y this procedure and, of the 20 clones that were selected from the final pool of phage, there was . . .

:: . - . : . . . . . .. . .. .

. ~ - . . . .. . ~ . . . ; . ..
. ,, ., .,. . : ,. . .

.. . . . .. . ...
., . -. . . . . . : . . . .
. .. - . . : . , ~ . . ... . .. .

WO91/19818 2 ~ PCT/US9l/04~ ;

only one repeat (the nuc~eotide sequence was also identical).

Dissociation tl/2 Equilibrium IC50 (minutes) (nM) Control Peptides YGGFL * 18.2 6.6 + 3.5 YGFWGM* 0.25 350 YAGFAQ* ** 8300 Peptides isolated with 50pM Fab YGAFQG 18.9 27 + 2~0 YGGFLT 17.9 YGYWSL 15.6 YGAFMQ 13.7 13 + 4.9 YGA~FQ 13.4 YGAFFK 9.1 59 + 22 YGFWSN 7.4 YGAFGG 5.0 YGGFGF 4.7 6~ + 18 YGVFSR 2.8 YGGLSM 0.96 YGTFLN 0.75 470 + 140 YGGLVR 0.50 YGSFSL 0.43 YGAWYT ** 1600 + 300 YGRFFH **
YGGLRH
YGSFMA **
YGGFSP **
** indicates that initial binding was not detected Dç~çx~ination of the dissociation of [l2sIlFab from fusion phage clones.
An assay employing the anti-phage antisera was developed to determine the rate of dissociation of :
[125I]Fab from individual phage isolates. Individual , - ~; . ., , . . .. , . . . . , . . , . . ~ ........... ...... : , . - .,, . . . ,. : ~ . . : .. . : , WO91/19818 ~ LI~ PCT/US9l/~

fusion phase isolates were amplified in a 5 ml liquid culture of E. coli K91 cells and phage particles were isolated and quantitated as described above. In 1 ml microtiter minitubes, 25 ~1 of TBS containing approximately 2 x 109 infectious phage particles were incubated with 25 ml of TBS/0.1% BSA containing 40,000 cpm of [l25I]Fab for 10 minutes. Anti-phage antisera ~25 ~1 of 1:1000 dilution in PBS/0.1%BSA) and staph A
particles coated with goat anti-mouse IgG (25 ~1 of Tachisorb diluted eight-fold in TBS/0.1% BSA) were then added. Dissociation was initiated after 2 hours further incubation at 4-C. To prevent binding of unbound [125I]Fab, 25 ~1 of a 400 ~M solution of YGGFL in PBS/0.1%
BSA was added to all tubes and the amount of phage-bound [l25I]Fab was determined by automated filtration on glass fiber filters previously treated with 1% BSA. Filter bound radioactivity was determined by gamma counting.
Binding was determined in triplicate prior to and 0.5, 1, 2, 4, 8, 16, 32 minutes after the addition of YGGFL
peptide. The time corresponding to a 50% reduction of initially bound [l25I]Fab was determined by linear regression of a semi-logarithmic plot of amount bound vs.
time. This assay was calibrated with library phage clones bearing peptides of known affinity (YGGFL, 7nM and YGFWGM, 350 nM), as shown in Fig. 7.
Shown in Table 6 are the tl/2 values for the ; phage clones that were picked from the pool of phage isolated using 5 pM Fab. Several of the clones had tl/2 values similar to the control phage YGGFL. Specific binding of [l25I]Fab was not detected for 5 of the 20 clones that were examined.
For a series of related ligands, the rank order of disso~iation rates should correlate with the rank order of eguilibrium binding constants (Kds). This correlation was confirmed and a quantitative relationship established between dissociation rates and the Xd of the corresponding free peptide. In addition, the affinity '' '.' : :
. ~
...

: ' . i :' '' ' ' . ' ' ' -: ', . .

WO91~19818 ~ ~ 8 ~ PcT/Us9l/o4~

requirements for selection using low Fab concentrations were established.
Several peptides corresponding to those phage clones with differing dissociation rates were chemically synthesized and their potencies were determined in a solution competition assay. The tl/2 values correlated with the IC50 of the corresponding free peptide. Under the conditions of the competition assay (low concentration of tracer, <20% bound tracex, 18 hr.
incubation), the IC50 should approximate the Kd. For phage bearing peptides with Kds greater than 500 nM, specific binding was not detected under these monovalent assay conditions.

EXAMPLE IV
Conotoxin Peptide Libraries Having Conserved Disulfide Frameworks.

A conotoxin peptide library is prepared as - generally described above, by synthesizing oligonucleotides containing degenerate codons of the NNK
(or NNS) motif. Here N is equimolar A,C,G, or T, and K
is equimolar G or T (S=G or C~. This motif codes for all 20 amino acids at each locus in the hypervariable regions. (Alternatively, the degenerate portion can be assembled by the condensation of 20 activated trinucleotides, one for each amino acid.) The six cysteine codons are preserved to produce the characteristic conotoxin frameworks.
To sample additional diversity in the peptide librarieæ, the number of residues between the Cys's is varied. This is accomplished as follows:
(l) Five separate oligonucleotide synthesis columns are prepared with the first nucleotide im~obilized on resin. (2) The common regions of the 3' end of the oligonucleotides is synthesized (all columns :' - . . . . . ..

:
: . -WO 91/19818 2 !~ 3 "5 1~1 1 i PCI'/US91/~14384 go through the same cycles to produce the cloning site, etc., on this end). Synthesis on all columns is carried out through the first Cys (or CysCys) of the cono-framework. (3) On column 1, two degenerate codons are synthesized; on column 2, three degenerate codons are synthesized, on so on. Each column now has oligonucleotides with either 2,3,4,5, or 6 degenerate codons in the first hypervariable region. (4) one Cys codon is now added to all columns (this is the second Cys of the omega class or the third Cys of the mu class).
(5) The resins from all five columns are removed, mixed well, and reallocated among the five columns. Each column now contains oligonucleotides with all five lengths of first hypervariable region. (6) Each column is again put through either 2,3,4,5, or 6 cycles of degenerate codon synthesis as before; and the next Cys codon (or CysCys for omega) is added. (7) The resins are again removed, mixed, and redistributed to the five columns, and the process is repeated through three (for mu) of four (for omega) hypervariable regions. (8) The common sequence on the 5' end of all the oligonucleotides is synthesized, and the oligonucleotides are removed from the resins and purified as usual. -~
Folding of the peptides to achieve biological activity may be directed by a 40 amino acid - conserved "leader peptide" at the N-term:inus of the pretoxin molecule. Synthesized as part of a recombinant fusion protein, this leader may enhance the folding of many of the members of the library into the "correct"
conotoxin-like framework. Alternatively, allowing the cysteine framework to form in a random manner produces a variety of structures, only some of which mimic the conotoxin framework. ~his collection provides additional multi-loop structures that add to the diversity of the peptide library.
` To minimize the possibility that one conformation would predominate, a gentle reduction of the :; :

. ~ ' ', -: ' . . ' . .: .
-.~ - ; - . , - :

.
. ,.,, - . : .
:~, . ' . ' . - :

WO91/19818 2 ~ 1 PCT~US9~
.

phage n vitro is employed, followed by mild oxidation to form most of the conformations. Mild reduction/oxidation can be accomplished by treatment with 0.2 to 5 mM DTT
followed by extensive dialysis to non-reducing conditions. A regenerable, immobilized lipoic acid column to rapidly pass the peptide-bearing particles over can also be used.
The possibility of promiscuous binding of Cys residues in the peptide binding to other proteins can also be minimized by mild reduction and oxidation, or can be avoided by re-engineering the fusion protein by site-directed mutagenesis to remove the Cys residues.
Peptides with the conotoxin framework can be expressed in several types of libraries as described herein. For example, the peptides can be 1) expressed in an N-terminal library in phage fAFFl; 2) expressed internally, fused to pIlI at or near the N-terminus, displacing the degenerate peptides 2 to lO or more residues from the cleavage point to circumvent processing problems; 3) expressed in a carboxy terminal exposed library (as many of the conotoxins are C-terminally amidated, residues with amino side chains can be added to the C-terminal end of the peptides, or the peptide library, can be amidated in vitro); and 4) the putative 40 residue "folding peptide" can be installed upstream of degenerate peptides displayed in the C-terminally exposed configuration.
This general format for using the secondary framework structure of conotoxins can also be applied to other peptide families with biological acti~ities as a basis for designing and constructing peptide expression/screening libraries in accordance with the present invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will .

-~ - - - ~ ' ~ -.: , WO~1/19818 2 ~ PCT/USgl/04~

be apparent that certain changes and modifications may be practiced within the scope of the appended claims.

- : ; ~ . ............... ~ . . .

: : : .: . . , :.: . , : , ;: - ::
. : ~ . -. . ; ~ .; ', ,, , .,. ;:

Claims (45)

WHAT IS CLAIMED IS:
1. A method for identifying peptides of interest which bind to a preselected receptor, comprising:
transforming host cells with a bacteriophage expression vector which comprises an oligonucleotide library of at least about 106 members which encode peptides, wherein a library member is joined in reading frame to the 5' region of a nucleotide sequence encoding an outer structural protein of the bacteriophage;
cultivating the transformed host cells under conditions suitable for expression and assembly of bacteriophage;
contacting bacteriophage that express the peptides to the preselected receptor under conditions conducive to specific peptide-receptor binding; and selecting bacteriophage which bind to the receptor and therefrom identifying the peptides of interest.
2. The method of claim 1, further comprising the step of determining the nucleotide sequence encoding the peptide of interest in the selected bacteriophage.
3. The method of claim 1, wherein the selected bacteriophage are propagated and the contacting and selecting steps are repeated to enrich for bacteriophage which express the peptides of interest.
4. The method of claim 3, wherein the valency of the specific peptide-receptor binding interaction is reduced in subsequent repetitions of the contacting, selecting and propagating steps to enrich for peptides of higher binding affinity.
5. The method of claim 1, wherein the bacteriophage expressing peptides and receptor are present at concentrations that produce a substantially monovalent binding interaction between the receptor and bacteriophage which express peptides of interest.
6. The method of claim 5, wherein the contacting step under substantially monovalent binding conditions is repeated at least once between additional rounds of propagation of the selected bacteriophage.
7. The method of claim 6, wherein the receptor is monovalent.
8. The method of claim 7, wherein the monovalent receptor is a Fab fragment of an antibody.
9. The method of claim 1, further comprising determining a dissociation rate for the peptide of interest and the receptor under substantially monovalent peptide-receptor binding conditions and therefrom determining the binding affinity of the peptide of interest for the receptor.
10. The method of claim 1, where the receptor is bound to a solid phase and the selected bacteriophage are separated from the culture.
11. The method of claim 10, wherein said receptor is an antibody or binding fragment thereof.
12. The method according to claim 1, wherein the outer protein is a bacteriophage coat protein.
13. The method of claim 1, wherein the bacteriophage encoded by the expression vector is a filamentous phage.
14. The method of claim 13, wherein the filamentous bacteriophage is fl, fd, or M13.
15. The method of claim 14, wherein the bacteriophage is fd or a derivative thereof.
16. The method of claim 15, wherein the outer bacteriophage protein is a coat protein.
17. The method of claim 16, wherein the coat protein of the fd bacteriophage is pIII.
18. The method of claim 1, wherein the oligonucleotide library comprises a series of codons encoding a random collection of amino acids.
19. The method of claim 18, wherein the codons encoding the collection of amino acids are represented by (NNK)x or (NNS)x, where N is A, C, G or T, K is G or T, S
is G or C, and x is from 5 to 8.
20. The method of claim 19, wherein the series of codons encoding the random collection of amino acids of the oligonucleotide library member encodes a hexa-peptide.
21. The method of claim 19, wherein x is 8 and the recombinant bacteriophage screened in the selecting step represents up to about 10% of the possible octapeptides.
22. The method of claim 18, wherein the oligonucleotide library member further encodes at least one spacer residue.
23. The method of claim 22, wherein a spacer residue comprises Gly.
24. The method of claim 23, wherein the spacer comprises Gly-Gly.
25. The method of claim 18, wherein the oligonucleotide library is flanked by nucleotide sequences that encode conserved residues that comprise structural frameworks for peptides of interest.
26. The method of claim 25, wherein the flanking sequences encode Cys residues.
27. The method of claim 26, wherein the Cys residues flank the N- and C- terminals of the peptide of interest.
28. The method of claim 26, wherein at least one conserved Cys residue is encoded within the library variable region.
29. The method of claim 25, wherein the structural framework comprises that of a conotoxin-like peptide and the conserved residues are Cys.
30. The method of claim 29, wherein the sequence of the structural framework comprises Cys-Cys-Y-Cys-Y-Cys-Cys or Cys-Y-Cys-Y-Cys-Cys-Y-Cys-Y-Cys, wherein Y is (NNK)x or (NNS)x, where N is A, C, G or T, K is G or T, S
is G or C, and x is from 2 to 6.
31. The method of claim 18, wherein the variable codon region is prepared from a condensation of activated trinucleotides.
32. The method of claim 18, wherein fragments of 20 to 100 basepairs of a gene which encodes a known ligand for the preselected receptor are cloned into the oligonucleotide library.
33. The method of claim 1, wherein the host cells are transformed by electroporation.
34. The method of claim 1, wherein the oligonucleotide library comprises at least about 108 members.
35. The method of claim 1, wherein the oligonucleotide library members are inserted in the bacteriophage expression vector so that the N-terminus of the processed bacteriophage outer protein is the first residue of the peptide.
36. The method of claim 1, wherein the bacteriophage protein is a preprotein which is processed by the host cell to leave the peptide encoded by an oligonucleotide library member exposed at the N-terminus of the mature outer structural protein.
37. The method according to claim 36, wherein the peptide comprises spacer amino acid residues are encoded by the oligonucleotide library members between the N-terminus of the mature outer protein and the C-terminus of the peptide.
38. A method for identifying peptides of interest which bind to a preselected receptor, comprising:
transforming host cells with a bacteriophage expression vector which comprises an oligonucleotide library which encodes peptides, wherein a library member is joined in reading frame with a nucleotide sequence to encode a fusion protein, wherein the library member represents the 5' member of the fusion protein and the 3' member comprises at least a portion of an outer structural protein of the bacteriophage;
cultivating the transformed cell under conditions suitable for expression and assembly of bacteriophage;

contacting bacteriophage that express the peptides to the preselected receptor under conditions conducive to specific peptide-receptor binding; and selecting bacteriophage which bind to the receptor and therefrom identifying the peptides of interest.
39. A composition comprising a peptide produced according to the method of claim 1, 13, 19, 31 or 38.
40. The composition of claim 39, wherein the peptide binds an antibody.
41. An oligonucleotide library produced according to claims 1, 13, 19, 31 or 38.
42. A host cell transformed with a bacteriophage expression vector which comprises an oligonucleotide library member, joined in reading frame to the 5' region of a nucleotide sequence encoding an outer structural protein of the bacteriophage, wherein the library member encodes a peptide of at least about five to twenty-five amino acids.
43. The host cell of claim 42, wherein the oligonucleotide library member comprises a series of codons encoding a random collection of from five to eight amino acids.
44. The host cell of claim 43, wherein the oligonucleotide library member further comprises a sequence encoding at least about one to five spacer amino acids which are expressed adjacent to the random collection of amino acids.
45. A collection of filamentous bacteriophage having a peptide on the N-terminus of a coat protein, wherein the peptide is coded for by a oligonucleotide library member from a randomly generated mixture of oligonucleotides.
CA002084411A 1990-06-20 1991-06-19 Peptide library and screening systems Abandoned CA2084411A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US541,108 1990-06-20
US07/541,108 US5723286A (en) 1990-06-20 1990-06-20 Peptide library and screening systems

Publications (1)

Publication Number Publication Date
CA2084411A1 true CA2084411A1 (en) 1991-12-21

Family

ID=24158208

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002084411A Abandoned CA2084411A1 (en) 1990-06-20 1991-06-19 Peptide library and screening systems

Country Status (6)

Country Link
US (3) US5723286A (en)
EP (1) EP0535151A4 (en)
JP (1) JPH05508321A (en)
AU (1) AU663055B2 (en)
CA (1) CA2084411A1 (en)
WO (1) WO1991019818A1 (en)

Families Citing this family (448)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590689B2 (en) * 1985-03-30 2006-08-16 KAUFFMAN, Stuart A. Method for obtaining DNA, RNA, peptides, polypeptides or proteins by means of a DNA-recombinant technique
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US7413537B2 (en) * 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
AU8740491A (en) * 1990-09-28 1992-04-28 Protein Engineering Corporation Proteinaceous anti-dental plaque agents
US5698426A (en) * 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US6258530B1 (en) 1990-09-28 2001-07-10 Ixsys, Inc. Surface expression libraries of randomized peptides
US6893845B1 (en) 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
US5770434A (en) * 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5871974A (en) * 1990-09-28 1999-02-16 Ixsys Inc. Surface expression libraries of heteromeric receptors
DE69129154T2 (en) * 1990-12-03 1998-08-20 Genentech Inc METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
DE69132843T2 (en) * 1990-12-06 2002-09-12 Affymetrix Inc N D Ges D Staat Identification of nucleic acids in samples
WO1992011272A1 (en) * 1990-12-20 1992-07-09 Ixsys, Inc. Optimization of binding proteins
EP1820858B1 (en) * 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
IE921169A1 (en) * 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
DE69217497T2 (en) * 1991-09-18 1997-06-12 Affymax Tech Nv METHOD FOR SYNTHESISING THE DIFFERENT COLLECTIONS OF OLIGOMERS
ATE463573T1 (en) * 1991-12-02 2010-04-15 Medimmune Ltd PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
US5869644A (en) * 1992-04-15 1999-02-09 The Johns Hopkins University Synthesis of diverse and useful collections of oligonucleotidies
EP0638089B2 (en) 1992-04-15 2008-03-05 The Johns Hopkins University Synthesis of diverse and useful collections of oligonucleotides
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US6114114A (en) * 1992-07-17 2000-09-05 Incyte Pharmaceuticals, Inc. Comparative gene transcript analysis
US6303297B1 (en) 1992-07-17 2001-10-16 Incyte Pharmaceuticals, Inc. Database for storage and analysis of full-length sequences
US5840484A (en) * 1992-07-17 1998-11-24 Incyte Pharmaceuticals, Inc. Comparative gene transcript analysis
PT663953E (en) * 1992-09-04 2002-05-31 Scripps Research Inst FAGEMIDES THAT CO-EXPRESSED A SURFACE RECEPTOR AND A HETEROLOGICAL SURFACE PROTEIN
US5807683A (en) * 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
AU6235294A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
AU6171194A (en) * 1993-02-05 1994-08-29 Affymax Technologies N.V. Receptor-binding antiproliferative peptides
US5512435A (en) * 1993-02-05 1996-04-30 Renschler; Markus F. Receptor-binding antiproliferative peptides
EP0693183B1 (en) * 1993-04-16 2002-07-24 The Regents of the University of California Methods for diabetes susceptibility assessment in asymptomatic patients
WO1994024959A1 (en) * 1993-04-27 1994-11-10 Symbiotech, Inc. Method of detecting compounds utilizing chemically modified lambdoid bacteriophage
IT1270939B (en) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio PROCEDURE FOR THE PREPARATION OF IMMUNOGEN AND DIAGNOSTIC REAGENTS, AND IMMUNOGEN AND DIAGNOSTIC REAGENTS SO OBTAINABLE.
JPH08510325A (en) * 1993-05-28 1996-10-29 カイロン コーポレイション Methods for selecting biologically active peptide sequences
WO1995010296A1 (en) * 1993-10-12 1995-04-20 Glycomed Incorporated A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5594120A (en) * 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
WO1995027901A1 (en) * 1994-04-11 1995-10-19 Ixsys, Inc. Class i peptide binding motifs
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5525735A (en) * 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5525734A (en) * 1994-06-22 1996-06-11 Affymax Technologies N.V. Methods for synthesizing diverse collections of pyrrolidine compounds
WO1996003418A1 (en) * 1994-07-26 1996-02-08 The Scripps Research Institute Soluble combinatorial libraries
US5939268A (en) * 1994-07-26 1999-08-17 The Scripps Research Institute Combinatorial libraries of molecules and methods for producing same
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
AU3719395A (en) * 1994-09-21 1996-04-09 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
EP0786085A4 (en) * 1994-10-14 1999-02-03 Chiron Mimotopes Pty Ltd Method and apparatus for efficient mimotope discovery
ATE235504T1 (en) * 1994-12-30 2003-04-15 Chiron Corp METHOD FOR THE CONTROLLED SYNTHESIS OF ANY PEPTIDE MIXTURES ENCODING POLYNUCLEOTIDE MIXTURES
AU3204895A (en) * 1995-02-01 1996-08-21 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
US6309820B1 (en) 1995-04-07 2001-10-30 University Of North Carolina At Chapel Hill Polypeptides having a functional domain of interest and methods of identifying and using same
CA2217641A1 (en) 1995-04-07 1996-10-10 Cytogen Corporation Polypeptides having a functional domain of interest and methods of identifying and using same
GB9507366D0 (en) * 1995-04-08 1995-05-31 Zeneca Ltd Assay
US6416714B1 (en) 1995-04-25 2002-07-09 Discovery Partners International, Inc. Remotely programmable matrices with memories
US5961923A (en) * 1995-04-25 1999-10-05 Irori Matrices with memories and uses thereof
US6025129A (en) * 1995-04-25 2000-02-15 Irori Remotely programmable matrices with memories and uses thereof
US6100026A (en) * 1995-04-25 2000-08-08 Irori Matrices with memories and uses thereof
US6017496A (en) 1995-06-07 2000-01-25 Irori Matrices with memories and uses thereof
US6284459B1 (en) 1995-04-25 2001-09-04 Discovery Partners International Solid support matrices with memories and combinatorial libraries therefrom
US5874214A (en) 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
US5751629A (en) 1995-04-25 1998-05-12 Irori Remotely programmable matrices with memories
US5741462A (en) 1995-04-25 1998-04-21 Irori Remotely programmable matrices with memories
US5925562A (en) * 1995-04-25 1999-07-20 Irori Remotely programmable matrices with memories
US6331273B1 (en) 1995-04-25 2001-12-18 Discovery Partners International Remotely programmable matrices with memories
US6329139B1 (en) 1995-04-25 2001-12-11 Discovery Partners International Automated sorting system for matrices with memory
CZ291749B6 (en) 1995-06-07 2003-05-14 Glaxo Group Limited Peptide compound binding to and activating the thrombopoietin receptor and pharmaceutical composition
US6410775B1 (en) * 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US6475806B1 (en) * 1995-06-07 2002-11-05 Praecis Pharmaceuticals, Inc. Anchor libraries and identification of peptide binding sequences
AU716466B2 (en) * 1995-09-27 2000-02-24 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
US6953663B1 (en) 1995-11-29 2005-10-11 Affymetrix, Inc. Polymorphism detection
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
DK0868427T3 (en) * 1995-12-18 2003-09-15 Praecis Pharm Inc Methods for identifying compounds that bind to a target
AU1206397A (en) 1995-12-29 1997-07-28 Guilford Pharmaceuticals Inc. Method and kit for detection of multiple protein interactions
AU725716C (en) 1996-01-23 2003-02-20 Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6031071A (en) * 1996-01-24 2000-02-29 Biophage, Inc. Methods of generating novel peptides
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US6190856B1 (en) 1996-05-22 2001-02-20 The Johns Hopkins University Methods of detection utilizing modified bacteriophage
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
WO1998002571A1 (en) * 1996-07-16 1998-01-22 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
EP2058400B1 (en) * 1996-08-19 2016-05-18 MorphoSys AG Vectors/DNA-Sequences from Human Combinatorial Antibody Libraries
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US5922537A (en) * 1996-11-08 1999-07-13 N.o slashed.AB Immunoassay, Inc. Nanoparticles biosensor
US5942422A (en) * 1996-11-14 1999-08-24 The Trustees Of Columbia University In The City Of New York Method for generating a directed, recombinant fusion nucleic acid
WO1998031700A1 (en) 1997-01-21 1998-07-23 The General Hospital Corporation Selection of proteins using rna-protein fusions
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US8207093B2 (en) * 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US7053177B1 (en) 1997-05-15 2006-05-30 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
US7135457B1 (en) 1997-05-15 2006-11-14 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
US6703362B1 (en) 1997-05-15 2004-03-09 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
WO1999002733A1 (en) * 1997-07-07 1999-01-21 Florida State University Identification of molecular targets
US6897028B1 (en) 1997-07-07 2005-05-24 Florida State University Identification of molecular targets
WO1999006587A2 (en) * 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
GB9717652D0 (en) * 1997-08-20 1997-10-22 Nycomed Imaging As Method
US20030148263A1 (en) * 1997-08-29 2003-08-07 Selective Genetics, Inc. Methods and compositions using genetic package display
WO1999027964A1 (en) * 1997-12-01 1999-06-10 Cfy Biomedicals, Inc. Multivalent recombinant antibodies for treating hrv infections
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
DE19805334A1 (en) * 1998-02-11 1999-08-12 Otogene Biotechnologische Fors Process for the development of an active pharmaceutical ingredient
AU3363399A (en) * 1998-03-27 1999-10-18 President And Fellows Of Harvard College Aptamer based bacterial inhibition systems (abbis)
EP1066404A4 (en) * 1998-04-03 2004-04-07 Invitrogen Corp Methods for producing libraries of expressible gene sequences
WO1999055911A1 (en) * 1998-04-24 1999-11-04 Fang Fang Identifying peptide ligands of target proteins with target complementary library technology (tclt)
DK1078051T3 (en) * 1998-05-13 2008-04-07 Domantis Ltd Phage display selection system for selection of properly folded proteins
JP2002522029A (en) 1998-07-27 2002-07-23 ジェネンテック・インコーポレーテッド Improved transformation efficiency in phage display by modification of coat protein
EP1105360B1 (en) 1998-08-17 2009-07-29 Bristol-Myers Squibb Company Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules
US20070178475A1 (en) * 1998-09-17 2007-08-02 Nehls Michael C Novel human polynucleotides and polypeptides encoded thereby
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
EP1124961B9 (en) 1998-10-23 2010-07-21 Kirin-Amgen Inc. Thrombopoietic compounds
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
ATE291099T1 (en) * 1999-01-22 2005-04-15 Ml Lab Plc SELECTION METHODS USING PREDICT ENZYME SYSTEM
IL145775A0 (en) 1999-04-12 2002-07-25 Agensys Inc 13 transmembrane protein expressed in prostate cancer
EP1792989A1 (en) 1999-04-12 2007-06-06 Agensys, Inc. 13 Transmembrane protein expressed in prostate cancer
US20020110809A1 (en) * 1999-04-30 2002-08-15 Nehls Michael C. Novel human polynucleotides and polypeptides encoded thereby
US20020095031A1 (en) * 1999-05-04 2002-07-18 Nehls Michael C. Novel human polynucleotides and polypeptides encoded thereby
WO2000070100A1 (en) * 1999-05-14 2000-11-23 New England Biolabs, Inc. Surface display of selenocysteine-containing peptides
US20050048548A1 (en) * 1999-05-14 2005-03-03 Christopher Noren Surface display of selenocysteine-containing peptides
ES2327382T3 (en) 1999-07-20 2009-10-29 Morphosys Ag METHODS FOR SUBMITTING (POLI) PEPTIDES / PROTEINS IN PARTICLES OF BACTERIOPHAGES THROUGH DISULFIDE LINKS.
US6653151B2 (en) 1999-07-30 2003-11-25 Large Scale Proteomics Corporation Dry deposition of materials for microarrays using matrix displacement
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
US6713309B1 (en) 1999-07-30 2004-03-30 Large Scale Proteomics Corporation Microarrays and their manufacture
US6602501B1 (en) 1999-08-12 2003-08-05 Agensys, Inc. C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
AU7099400A (en) * 1999-09-03 2001-04-10 Beth Israel Deaconess Medical Center Methods and reagents for regulating gene expression
US7297478B1 (en) * 2000-09-22 2007-11-20 Large Scale Biology Corporation Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
ES2316387T3 (en) 1999-10-05 2009-04-16 Agensys, Inc. RECEPTOR COUPLED TO OVERPRINTED PROTEIN G IN PROSTATE CANCER AND THE USE OF IT.
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
WO2001036006A1 (en) * 1999-11-19 2001-05-25 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
US6703480B1 (en) * 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
JP2003516755A (en) * 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド Shotgun scanning, a combined method for mapping functional protein epitopes
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR20020070469A (en) * 1999-12-27 2002-09-09 도레이 가부시끼가이샤 Cytokine-like peptide
US7022479B2 (en) * 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
ATE322558T1 (en) 2000-01-24 2006-04-15 Compound Therapeutics Inc SENSITIVE AND MULTIPLEX DIAGNOSTIC TESTS FOR PROTEIN ANALYSIS
AU2001233043A1 (en) 2000-01-28 2001-08-07 Linden Technologies, Inc. C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support
US7102024B1 (en) * 2000-08-01 2006-09-05 Schwartz David A Functional biopolymer modification reagents and uses thereof
US6686461B1 (en) 2000-03-22 2004-02-03 Solulink Bioscience, Inc. Triphosphate oligonucleotide modification reagents and uses thereof
JP2003531588A (en) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド Multivalent antibodies and their uses
JP4966470B2 (en) 2000-04-14 2012-07-04 ダニスコ・ユーエス・インコーポレーテッド Selective targeting method
US7129326B2 (en) 2000-04-14 2006-10-31 Genencor International, Inc. Methods for selective targeting
MXPA02010324A (en) 2000-04-21 2003-04-25 Amgen Inc Apo ai aii peptide derivatives.
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
CA2407956A1 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides as therapeutic agents
US20030054348A1 (en) * 2000-05-09 2003-03-20 Blume Arthur J. Methods of identifying the activity of gene products
US20020110843A1 (en) * 2000-05-12 2002-08-15 Dumas David P. Compositions and methods for epitope mapping
US20040168209A1 (en) * 2000-06-12 2004-08-26 Alejandro Abuin Novel murine polynucleotide sequences and mutant cells and mutant animals defined thereby
US20050158838A1 (en) * 2000-06-19 2005-07-21 Dyax Corp., A Delaware Corporation Novel enterokinase cleavage sequences
AU6855901A (en) 2000-06-19 2002-01-02 Dyax Corp Novel enterokinase cleavage sequences
EP2075582A3 (en) 2000-07-12 2010-01-06 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
AU2001279055A1 (en) 2000-07-27 2002-02-13 Genentech, Inc. Apo-2L receptor agonist and CPT-11 synergism
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
DE10041238A1 (en) * 2000-08-22 2002-03-07 Aventis Res & Tech Gmbh & Co Process for the identification of specifically cleavable peptides and use of such peptide sequences
WO2002018578A2 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
US6539102B1 (en) 2000-09-01 2003-03-25 Large Scale Proteomics Reference database
US6980674B2 (en) * 2000-09-01 2005-12-27 Large Scale Proteomics Corp. Reference database
WO2002046400A2 (en) * 2000-12-08 2002-06-13 The Board Of Trustees Of The University Of Illinois Mutated class ii major histocompatibility proteins
US7132510B2 (en) * 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20030009293A1 (en) * 2001-01-09 2003-01-09 Anderson Norman G. Reference database
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
AU2002342669C1 (en) 2001-05-11 2010-10-07 Amgen, Inc. Peptides and related molecules that bind to TALL-1
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP1406493A4 (en) * 2001-06-11 2006-06-14 Xenoport Inc Administration of agents via the pept-2 transporter
JP4444651B2 (en) 2001-06-14 2010-03-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア BCR-ABL tyrosine kinase mutations associated with resistance to STI-571
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DK2000545T3 (en) 2001-06-20 2011-11-28 Genentech Inc Compositions and methods for diagnosis and treatment of lung tumor
US7727713B2 (en) 2001-06-20 2010-06-01 Nuevolution A/S Templated molecules and methods for using such molecules
EP1493028A4 (en) * 2001-07-06 2006-06-14 Genentech Inc Phage displayed pdz domain ligands
US7858560B2 (en) 2001-07-16 2010-12-28 Caprotec Bioanalytics Gmbh Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
US20030143612A1 (en) * 2001-07-18 2003-07-31 Pointilliste, Inc. Collections of binding proteins and tags and uses thereof for nested sorting and high throughput screening
WO2003062370A2 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
US20050032243A1 (en) * 2001-07-25 2005-02-10 Pollack Gary M. Method and apparatus for rapid determination of ligand-protein binding using charcoal adsorption
US20030104604A1 (en) * 2001-08-03 2003-06-05 Weiping Yang Genetically engineered bacterial strains for the display of foreign peptides on filamentous phage
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
MXPA04001804A (en) * 2001-08-30 2005-03-07 Biorexis Pharmaceutical Corp Modified transferrin fusion proteins.
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
CA2459318C (en) 2001-09-06 2017-09-26 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
CA2460120A1 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
AU2002367539A1 (en) * 2001-11-07 2003-09-16 Auburn University Phage ligand sensor devices and uses thereof
CA2469464A1 (en) * 2001-12-07 2003-06-19 Dyax Corporation Method and apparatus for washing magnetically responsive particles
JP2005525095A (en) 2002-01-02 2005-08-25 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
CA2472030A1 (en) * 2002-01-24 2003-07-31 Pointilliste, Inc. Use of collections of binding sites for sample profiling and other applications
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
AU2003224674A1 (en) * 2002-03-11 2003-09-29 Hk Pharmaceuticals, Inc. Compounds and methods for analyzing the proteome
NZ535144A (en) 2002-03-15 2006-03-31 Nuevolution As An improved method for synthesising templated molecules
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
MXPA04009778A (en) 2002-04-08 2004-12-13 Pionner Hi Bred International Enhanced silk exsertion under stress.
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
AU2003239966B9 (en) * 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
WO2003104415A2 (en) * 2002-06-05 2003-12-18 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040202665A1 (en) * 2002-07-01 2004-10-14 Janette Lazarovits Compositions and methods for therapeutic treatment
US20040208877A1 (en) * 2002-07-01 2004-10-21 Avigdor Levanon Antibodies and uses thereof
EP1539980B1 (en) 2002-08-01 2016-02-17 Nuevolution A/S Library of complexes comprising small non-peptide molecules and double-stranded oligonucleotides identifying the molecules
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
CN1694895A (en) * 2002-08-30 2005-11-09 比奥雷克西斯药物公司 Modified transferrin-antibody fusion proteins
US8557743B2 (en) * 2002-09-05 2013-10-15 Dyax Corp. Display library process
DE10242286A1 (en) 2002-09-12 2004-03-18 Basf Ag Process for preparation of mono- or diesters of polyterahydrofuran by acid catalysed polymeriosation used ion preparation of polyurethane, polyesters and polyamiode elastomers
DK1542714T3 (en) 2002-09-18 2014-05-26 Janssen Pharmaceuticals Inc PROCEDURES FOR INCREASING PRODUCTION OF BLADETS AND HEMATOPOIETIC STEM CELLS
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
AU2003291677A1 (en) * 2002-10-30 2004-05-25 Pointilliste, Inc. Methods for producing polypeptide-tagged collections and capture systems containing the tagged polypeptides
DK3299463T3 (en) 2002-10-30 2020-12-07 Nuevolution As ENZYMATIC CODING
ATE466885T1 (en) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic METHODS OF PREVENTING AND TREATING CANCER METASTISATION AND BONE LOSS ASSOCIATED WITH CANCER METASTISATION
AU2003297808A1 (en) * 2002-12-09 2004-06-30 The Trustees Of Columbia University In The City Of New York Peptides and methods for deactivation of organophosphorus-based nerve agents and insecticides
US9121110B2 (en) 2002-12-19 2015-09-01 Nuevolution A/S Quasirandom structure and function guided synthesis methods
WO2004064972A2 (en) * 2003-01-16 2004-08-05 Hk Pharmaceuticals, Inc. Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
WO2004065416A2 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
EP1590453B1 (en) 2003-01-28 2013-11-27 Cellectis Custom-made meganuclease and use thereof
EP1947116B1 (en) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
CA2860151A1 (en) 2003-02-10 2004-08-26 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
AU2003290561A1 (en) * 2003-02-10 2004-09-06 Dana Ault-Riche Self-assembling arrays and uses thereof
EP1597395A2 (en) 2003-02-21 2005-11-23 Nuevolution A/S Method for producing second-generation library
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
WO2005014780A2 (en) 2003-05-30 2005-02-17 Agensys, Inc. Prostate stem cell antigen (psca) variants and subsequences thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
PT2272868E (en) 2003-06-05 2015-07-07 Genentech Inc Combination therapy for b cell disorders
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
US20050266009A1 (en) * 2003-06-30 2005-12-01 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
PL1641822T3 (en) 2003-07-08 2013-10-31 Genentech Inc Il-17 a/f heterologous polypeptides and therapeutic uses thereof
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
EP1663278A4 (en) * 2003-08-28 2009-07-29 Biorexis Pharmaceutical Corp Epo mimetic peptides and fusion proteins
ATE447626T1 (en) 2003-09-18 2009-11-15 Nuevolution As METHOD FOR OBTAINING STRUCTURAL INFORMATION FROM ENCODED MOLECULES AND FOR SELECTING COMPOUNDS
US20050095648A1 (en) * 2003-10-30 2005-05-05 Mario Geysen Method for designing linear epitopes and algorithm therefor and polypeptide epitopes
CA2747871C (en) 2003-11-17 2018-04-10 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20060018911A1 (en) * 2004-01-12 2006-01-26 Dana Ault-Riche Design of therapeutics and therapeutics
ATE452147T1 (en) 2004-02-19 2010-01-15 Genentech Inc ANTIBODIES WITH CORRECTED CDR
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP1789453A2 (en) * 2004-05-18 2007-05-30 Genentech, Inc. M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
EP2428522A1 (en) 2004-05-28 2012-03-14 Agensys, Inc. Antibodies that bind to PSCA proteins for diagnosis of cancer
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US8034553B2 (en) 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
US8143380B2 (en) * 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
HUE024953T2 (en) * 2004-08-23 2016-02-29 Yeda Res & Dev Peptide inhibitors for mediating stress responses
PT1784426E (en) 2004-09-03 2012-03-06 Genentech Inc Humanized anti-beta7 antagonists and uses therefor
BRPI0516011A (en) * 2004-09-24 2008-08-19 Amgen Inc modified fc molecules
AU2005310189A1 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US20100022402A1 (en) * 2004-11-23 2010-01-28 Sancar Adhya Methods and Compositions for the In Vitro High-Throughput Detection of Protein/Protein Interactions
US8022040B2 (en) * 2004-11-29 2011-09-20 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
RU2007137489A (en) 2005-03-10 2009-04-20 Дженентек, Инк. (Us) METHODS AND COMPOSITIONS FOR MODULATION OF VESSEL INTEGRITY
CA2603093A1 (en) 2005-03-31 2006-10-05 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
PE20061324A1 (en) 2005-04-29 2007-01-15 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
TW200716174A (en) 2005-05-19 2007-05-01 Centocor Inc Anti-MCP-1 antibodies, compositions, methods and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) * 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP2452694B1 (en) 2005-06-30 2018-11-14 Janssen Biotech, Inc. Anti-IL-23 antibodies, compositions, methods and uses
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
WO2007053358A2 (en) 2005-10-28 2007-05-10 Praecis Pharmaceuticals, Inc. Methods for identifying compounds of interest using encoded libraries
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
UA96139C2 (en) 2005-11-08 2011-10-10 Дженентек, Інк. Anti-neuropilin-1 (nrp1) antibody
ATE490318T1 (en) 2005-12-01 2010-12-15 Nuevolution As ENZYME-MEDIATING CODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP5808070B2 (en) * 2005-12-02 2015-11-10 ジェネンテック, インコーポレイテッド Binding polypeptides and uses thereof
PT3219328T (en) 2005-12-29 2020-08-28 Janssen Biotech Inc Human anti-il-23 antibodies, compositions, method and uses
US20070175313A1 (en) * 2006-01-31 2007-08-02 Kevin Vandervliet MP3 player holder assembly
WO2007109527A1 (en) * 2006-03-17 2007-09-27 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides
PL2005185T3 (en) 2006-03-22 2011-05-31 Viral Logic Systems Tech Corp Methods for identifying polypeptide targets
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
EP2614839A3 (en) 2006-04-05 2015-01-28 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
JP2009536527A (en) * 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド Binding polypeptide with optimized scaffold
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
CA2652570A1 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
BRPI0713272A2 (en) * 2006-06-12 2017-05-02 Receptor Biologix Inc receptor-specific therapeutic products on the surface of pan cells
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
JP5102833B2 (en) 2006-07-24 2012-12-19 バイオレクシス ファーマシューティカル コーポレーション Exendin fusion protein
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
JPWO2008032833A1 (en) 2006-09-14 2010-01-28 株式会社医学生物学研究所 Antibody with enhanced ADCC activity and method for producing the same
WO2008063776A2 (en) * 2006-10-12 2008-05-29 Genentech, Inc. Antibodies to lymphotoxin-alpha
AR064464A1 (en) * 2006-12-22 2009-04-01 Genentech Inc ANTIBODIES ANTI - INSULINAL GROWTH FACTOR RECEIVER
US20100279881A1 (en) * 2007-02-02 2010-11-04 Sompuram Seshi R Epitope-mediated antigen prediction
PE20090722A1 (en) * 2007-02-02 2009-07-13 Amgen Inc HEPCIDIN, HEPCIDIN ANTAGONISTS AND METHODS OF USE
US7834154B2 (en) 2007-02-09 2010-11-16 Genentech, Inc. Anti-ROBO4 antibodies and uses therefor
CN101663407B (en) 2007-02-22 2017-08-08 健泰科生物技术公司 method for detecting inflammatory bowel disease
US8318163B2 (en) 2007-05-17 2012-11-27 Genentech, Inc. Anti-pan neuropilin antibody and binding fragments thereof
JP5469600B2 (en) 2007-07-16 2014-04-16 ジェネンテック, インコーポレイテッド Anti-CD79b antibody and immunoconjugate and method of use thereof
AR067543A1 (en) 2007-07-16 2009-10-14 Genentech Inc ANTI-CD79B ANTIBODIES AND HUMANIZED IMMUNOCATE PLAYERS AND METHODS OF USE
ES2614735T3 (en) 2007-07-23 2017-06-01 Janssen Biotech, Inc. Methods and compositions for treating fibrosis-related disorders using IL-17 antagonists
EP2190987B1 (en) 2007-08-21 2012-11-14 MorphoSys AG Methods for the formation of disulphide bonds
PL2233149T3 (en) 2007-10-16 2016-08-31 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
WO2009052184A2 (en) * 2007-10-16 2009-04-23 Receptor Biologix, Inc. Compositions comprising optimized her1 and her3 multimers and methods of use thereof
US8129586B2 (en) 2007-11-20 2012-03-06 Pioneer Hi-Bred International, Inc. Maize ethylene signaling genes and modulation of same for improved stress tolerance in plants
TWI580694B (en) 2007-11-30 2017-05-01 建南德克公司 Anti-vegf antibodies
ES2500066T3 (en) 2008-01-25 2014-09-30 Amgen, Inc Ferroportin antibodies and methods of use
PE20091318A1 (en) 2008-01-31 2009-09-16 Genentech Inc ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE OF THE SAME
US20090233809A1 (en) * 2008-03-04 2009-09-17 Affymetrix, Inc. Resequencing methods for identification of sequence variants
AU2009246946B2 (en) 2008-05-01 2013-09-26 Amgen Inc. Anti-hepcidin antibodies and methods of use
CA2728473A1 (en) 2008-06-20 2009-12-23 National University Corporation Okayama University Antibody against oxidized ldl/.beta.2gpi complex and use of the same
EP2671891A3 (en) 2008-06-27 2014-03-05 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US9182406B2 (en) * 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
CA2733642A1 (en) 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
US10131693B2 (en) 2008-10-20 2018-11-20 Gwangju Institute Of Science And Technology Bipodal-peptide binder
CA3149920A1 (en) 2008-10-31 2010-05-06 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
DK2376535T3 (en) 2008-12-09 2017-06-12 Hoffmann La Roche ANTI-PD-L1 ANTIBODIES AND THEIR USE TO PROMOTE T CELL FUNCTION
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
AU2010213892B2 (en) 2009-02-12 2014-10-23 Janssen Biotech, Inc. Fibronectin type III domain based scaffold compositions, methods and uses
US8716553B2 (en) 2009-03-02 2014-05-06 Pioneer Hi Bred International Inc NAC transcriptional activators involved in abiotic stress tolerance
US8466260B2 (en) 2009-04-01 2013-06-18 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
US20110035843A1 (en) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
EP2478101A1 (en) 2009-09-16 2012-07-25 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
EP2305717A1 (en) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
CN102597775A (en) 2009-09-25 2012-07-18 佐马技术有限公司 Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011036555A1 (en) 2009-09-25 2011-03-31 University Of Oslo Multivalent phage display systems and methods
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
TWI507524B (en) 2009-11-30 2015-11-11 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
CA2782814A1 (en) 2009-12-02 2011-06-09 Amgen Inc. Binding proteins that bind to human fgfr1c, human .beta.-klotho and both human fgfr1c and human .beta.-klotho
EP2354245A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of hepatic PPAR- activity
EP2354244A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of liver-specific insulin resistance
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
ES2519348T3 (en) 2010-02-18 2014-11-06 Genentech, Inc. Neurregulin antagonists and their use in cancer treatment
SG183335A1 (en) 2010-02-23 2012-09-27 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
CA2832672A1 (en) 2010-04-16 2011-10-20 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2012047324A2 (en) 2010-06-10 2012-04-12 President And Fellows Of Harvard College Systems and methods for amplification and phage display
SG186983A1 (en) 2010-07-09 2013-02-28 Genentech Inc Anti-neuropilin antibodies and methods of use
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CA2808998A1 (en) 2010-08-17 2012-02-23 Stichting Katholieke Universiteit A novel method for diagnosing q-fever using a cellular immunological test
EP2619584B1 (en) 2010-09-21 2016-10-12 Stichting Katholieke Universiteit Novel method for diagnosing lyme disease using a cellular immunological test
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
EP2474612A1 (en) 2011-01-05 2012-07-11 University College Dublin, National University of Ireland Dublin Affinity separation means, and uses thereof to separate, purify or concentrate a target molecule
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
US20120213781A1 (en) 2011-02-11 2012-08-23 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
CA2831136A1 (en) 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
US20140088017A1 (en) 2011-05-23 2014-03-27 Yeda Research And Development Co., Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2714932A4 (en) 2011-05-24 2015-06-10 Univ California Genes dysregulated in autism as biomarkers and targets for therapeutic pathways
JP2014533927A (en) 2011-09-15 2014-12-18 ジェネンテック, インコーポレイテッド How to promote differentiation
KR20140084164A (en) 2011-10-15 2014-07-04 제넨테크, 인크. Scd1 antagonists for treating cancer
WO2013063006A1 (en) 2011-10-25 2013-05-02 Pioneer Hi-Bred International, Inc. Methods to alter plant cell wall composition for improved biofuel production and silage digestibility
PT2794626T (en) 2011-12-22 2018-01-12 Glycomimetics Inc E-selectin antagonist compounds
RU2014133547A (en) 2012-01-18 2016-03-10 Дженентек, Инк. WAYS OF APPLICATION OF FGF19 MODULATORS
AU2013216753B2 (en) 2012-02-11 2017-09-21 Genentech, Inc. R-spondin translocations and methods using the same
BR112014020173A8 (en) 2012-03-16 2017-07-11 Hoffmann La Roche METHODS FOR THE TREATMENT OF A MELANOMA, USES OF AN INHIBITOR, COMPOSITIONS, KIT, METHOD OF INHIBITION, METHOD OF IDENTIFICATION, METHOD OF ADJUSTING THE TREATMENT AND INVENTION
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
MX2014010943A (en) 2012-03-16 2014-11-26 Genentech Inc Engineered conformationally-stabilized proteins.
CN104583776B (en) 2012-04-25 2016-09-07 比奥德赛公司 For the method detecting the allosteric modulators of protein
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
CA2891514C (en) 2012-12-07 2020-08-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
JP2016509045A (en) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト How to treat cancer and prevent drug resistance
US9925240B2 (en) 2013-03-06 2018-03-27 Genentech, Inc. Methods of treating and preventing cancer drug resistance
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (en) 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
WO2014142646A1 (en) 2013-03-13 2014-09-18 Stichting Katholieke Universiteit Q-fever diagnostic
KR20150127216A (en) 2013-03-14 2015-11-16 제넨테크, 인크. Methods of treating cancer and preventing cancer drug resistance
US20160143910A1 (en) 2013-03-15 2016-05-26 Constellation Pharmaceuticals, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014144600A2 (en) 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
NZ712314A (en) 2013-03-15 2021-07-30 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
CN105247056A (en) 2013-03-15 2016-01-13 先锋国际良种公司 Modulation of acc deaminase expression
CN105308460A (en) 2013-05-02 2016-02-03 天主教大学基金会 Personalised medicine
WO2014201265A1 (en) 2013-06-14 2014-12-18 Pacific Biosciences Of California, Inc. Bis-biotinylation tags
KR102534681B1 (en) 2013-12-24 2023-05-18 잔센파마슈티카엔.브이. Anti-vista antibodies and fragments
WO2015116740A1 (en) 2014-01-28 2015-08-06 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
WO2015171523A1 (en) 2014-05-05 2015-11-12 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
MX2016015163A (en) 2014-05-23 2017-03-03 Genentech Inc Mit biomarkers and methods using the same.
CN107073121A (en) 2014-06-13 2017-08-18 基因泰克公司 Treatment and the method for prevention cancer drug resistance
EP3157945A4 (en) 2014-06-20 2017-11-22 F. Hoffmann-La Roche AG Chagasin-based scaffold compositions, methods, and uses
US10196613B2 (en) 2014-12-19 2019-02-05 Regeneron Pharmaceuticals, Inc. Stem cells for modeling type 2 diabetes
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
DK3280433T3 (en) 2015-04-06 2021-11-15 Subdomain Llc THE NOVO BINING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF
US10125198B2 (en) 2015-04-17 2018-11-13 Distributed Bio, Inc. Method for mass humanization of non-human antibodies
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
WO2016173719A1 (en) 2015-04-30 2016-11-03 Abcheck S.R.O. Method for mass humanization of rabbit antibodies
BR112017027870A2 (en) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv antibodies and anti-sight fragments
CN116987187A (en) 2015-09-23 2023-11-03 豪夫迈·罗氏有限公司 Optimized variants of anti-VEGF antibodies
EP3405190A4 (en) 2015-12-23 2019-10-30 Moonshot Pharma LLC Methods for inducing an immune response
BR112018016461A2 (en) 2016-02-12 2019-10-01 Janssen Pharmaceutica Nv antibodies and anti-sight fragments, their uses and their identification methods
CA3019164A1 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2018014039A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
MX2019000643A (en) 2016-07-15 2019-06-13 Poseida Therapeutics Inc Chimeric antigen receptors and methods for use.
AU2017302657A1 (en) 2016-07-29 2019-02-14 Regeneron Pharmaceuticals, Inc. Mice comprising mutations resulting in expression of c-truncated fibrillin-1
EP3509616A1 (en) 2016-09-09 2019-07-17 H. Hoffnabb-La Roche Ag Selective peptide inhibitors of frizzled
CA3037961A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
JP2020503842A (en) 2016-10-12 2020-02-06 ヤンセン バイオテツク,インコーポレーテツド Methods for screening modulators of GDF15-like biological activity
MX2019005661A (en) 2016-11-16 2019-10-07 Janssen Biotech Inc Method of treating psoriasis with anti-il-23 specific antibody.
CN110234351A (en) 2017-01-30 2019-09-13 詹森生物科技公司 For treating the anti-TNF antibodies, composition and method of activity psoriatic arthritis
MX2019009377A (en) 2017-02-07 2019-12-11 Janssen Biotech Inc Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis.
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
MX2019010219A (en) 2017-02-27 2020-02-07 Regeneron Pharma Humanized model of kidney and liver disorders.
US11744861B2 (en) 2017-03-13 2023-09-05 Poseida Therapeutics, Inc. Compositions and methods for selective elimination and replacement of hematopoietic stem cells
SG11201909048TA (en) 2017-04-21 2019-11-28 Genentech Inc Use of klk5 antagonists for treatment of a disease
EP3615569A1 (en) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
WO2018237326A1 (en) 2017-06-22 2018-12-27 1AlMOONSHOT PHARMA LLC Methods for treating cancer with compositions comprising amlexanox and immune modulators
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
EP3679145A2 (en) 2017-09-08 2020-07-15 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
TW201922780A (en) 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
EP3692370A2 (en) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Articles and methods directed to personalized therapy of cancer
JP7097440B2 (en) 2017-11-10 2022-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Non-human animals containing the SLC30A8 mutation and usage
EP3728321A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Use of pilra binding agents for treatment of a disease
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
EP3790587A4 (en) 2018-05-11 2022-01-26 Janssen Biotech, Inc. Methods of treating depression using il-23 antibodies
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
US11548941B2 (en) 2018-11-20 2023-01-10 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
JP2022513507A (en) 2018-12-20 2022-02-08 ポセイダ セラピューティクス,インコーポレイティド Nanotransposon composition and usage
WO2020183269A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
CA3133388A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
US20220144934A1 (en) 2019-03-14 2022-05-12 Janssen Biotech, Inc. Methods for Producing Anti-TNF Antibody Compositions
EA202192459A1 (en) 2019-03-18 2021-11-25 Янссен Байотек, Инк. METHOD FOR TREATMENT OF PSORIASIS WITH ANTIBODY TO IL12 / IL23 IN CHILDREN
JP2022524215A (en) 2019-03-28 2022-04-28 ダニスコ・ユーエス・インク Modified antibody
KR20220005568A (en) 2019-05-09 2022-01-13 제넨테크, 인크. Methods for making antibodies
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP2022535534A (en) 2019-06-03 2022-08-09 ヤンセン バイオテツク,インコーポレーテツド Anti-TNF Antibodies, Compositions and Methods for Treating Active Ankylosing Spondylitis
MX2021014885A (en) 2019-06-03 2022-04-06 Janssen Biotech Inc Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis.
CN114761424A (en) 2019-09-05 2022-07-15 波赛达治疗公司 Allogeneic cell compositions and methods of use
CN115135672A (en) 2019-12-20 2022-09-30 波赛达治疗公司 anti-MUC 1 compositions and methods of use
WO2021183795A1 (en) 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
MX2022012956A (en) 2020-04-14 2023-03-27 Poseida Therapeutics Inc Compositions and methods for use in the treatment of cancer.
US20210338833A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US20240000969A1 (en) 2020-10-21 2024-01-04 Poseida Therapeutics San Diego Compositions and methods for delivery of nucleic acids
AU2022308201A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
AU2022306144A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023060088A1 (en) 2021-10-04 2023-04-13 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023141576A1 (en) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359535A (en) * 1979-10-01 1982-11-16 George Pieczenik Autonomously replicating DNA containing inserted DNA sequences
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
EP0590689B2 (en) * 1985-03-30 2006-08-16 KAUFFMAN, Stuart A. Method for obtaining DNA, RNA, peptides, polypeptides or proteins by means of a DNA-recombinant technique
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
ATE165363T1 (en) * 1985-08-28 1998-05-15 George Pieczenik METHOD AND MEANS FOR SORTING AND DETERMINING BIOLOGICAL INFORMATION
EP0286200B1 (en) * 1987-01-12 1994-10-12 Stratagene DNA cloning vector with in vivo excisable plasmids
ATE114723T1 (en) * 1987-03-02 1994-12-15 Enzon Lab Inc ORGANISM AS CARRIER FOR ''SINGLE CHAIN ANTIBODY DOMAIN (SCAD)''.
WO1989006694A1 (en) * 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
US4910140A (en) * 1988-04-18 1990-03-20 Bio-Rad Laboratories, Inc. Electroporation of prokaryotic cells
CA1340288C (en) * 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP2919890B2 (en) * 1988-11-11 1999-07-19 メディカル リサーチ カウンスル Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016841C (en) * 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69128362T2 (en) * 1990-06-01 1998-05-20 Chiron Corp COMPOSITIONS AND METHOD FOR IDENTIFYING MOLECULES WITH BIOLOGICAL EFFECTIVENESS
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9022190D0 (en) * 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
DE69129154T2 (en) * 1990-12-03 1998-08-20 Genentech Inc METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
EP1820858B1 (en) * 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof

Also Published As

Publication number Publication date
US5432018A (en) 1995-07-11
JPH05508321A (en) 1993-11-25
EP0535151A1 (en) 1993-04-07
EP0535151A4 (en) 1993-06-09
AU663055B2 (en) 1995-09-28
US5723286A (en) 1998-03-03
WO1991019818A1 (en) 1991-12-26
US7553617B1 (en) 2009-06-30
AU8285291A (en) 1992-01-07

Similar Documents

Publication Publication Date Title
AU663055B2 (en) Peptide library and screening systems
US6107059A (en) Peptide library and screening method
US5270170A (en) Peptide library and screening method
Cwirla et al. Peptides on phage: a vast library of peptides for identifying ligands.
Clackson et al. In vitro selection from protein and peptide libraries
US7078166B2 (en) Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
Bonnycastle et al. Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage
EP1151143B1 (en) Selection of proteins using rna-protein fusions
US5498538A (en) Totally synthetic affinity reagents
US5733731A (en) Peptide library and screening method
US6031071A (en) Methods of generating novel peptides
Cesareni Peptide display on filamentous phage capsids An new powerful tool to study protein—ligand interaction
AU772069B2 (en) Protein isolation and analysis
US20080058217A1 (en) Selection of proteins using RNA-protein fusions
WO1998031700A1 (en) Selection of proteins using rna-protein fusions
US20020192789A1 (en) Novel enterokinase cleavage sequences
Caparon et al. Analysis of novel streptavidin-binding peptides, identified using a phage display library, shows that amino acids external to a perfectly conserved consensus sequence and to the presented peptides contribute to binding
CA2399809A1 (en) Combinatorial protein domains
Hogrefe et al. Cloning in a bacteriophage lambda vector for the display of binding proteins on filamentous phage
Kay Biologically displayed random peptides as reagents in mapping protein-protein interactions
JP3386210B2 (en) Methods for producing recombinant and synthetic peptides and their uses
WO2002012277A2 (en) Hybrid combinatorial proteins made from reshuffling of differently folded domains
AU2004201047A1 (en) Protein isolation and analysis

Legal Events

Date Code Title Description
FZDE Dead